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ABSTRACT 
There is considerable evidence that delays in diagnosing and treating 
breast cancer reduce long-term survival. The purpose of this study was to assess 
the waiting time between diagnosis and treatment for Alberta women with breast 
cancer and to examine the influence of age, cancer stage, Regional Health 
Authority (RHA), community size, and year of diagnosis on this time interval. 
The data were obtained from the Alberta Cancer Board. The information 
included approximately all Alberta women with breast cancer between 1997 and 
2000. 
The overall median waiting time was 17 days. The mean and median 
delay increased by an average of two days each year. Only 43.8% of cases were 
treated within the recommended 14 days. The delay was significantly longer for 
women younger than 70, with stage 1 disease and from Northern RHAs. Efforts 
must be made to decrease delay and ensure that all women receive equal access to 
health services. 
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CHAPTER 1: INTRODUCTION 
Breast cancer is a disease with a significant impact on women's health. In 
most western countries, it continues to be the most commonly diagnosed cancer 
among women (excluding non-melanoma skin cancer) and the second leading 
cause of female cancer deaths (1). In Canada, 1 in 9 women are expected to be 
diagnosed with breast cancer and 1 in 26 women are expected to die from it (2). 
Breast cancer accounts for 3 1 % of newly diagnosed cancers and 17% of cancer 
deaths in Canadian women (2). 
The exact causes of breast cancer are not known. However, research has 
provided information regarding personal characteristics and factors that increase 
the risk of developing this disease. Combining all of these known risk factors still 
only accounts for approximately 30% of cases (2). The strongest risk factors 
include being 50 years of age or older, a carrier of the BRCAj or B R C A 2 gene, a 
strong family history of breast cancer, being born in Northern Europe or North 
America, and previously having breast cancer (2). Experiencing longer exposure 
to estrogen either through an early menarche (before 12 years) or a late 
menopause (after 50 years) and late childbearing (after 30 years) are other well 
documented factors that can impact the likelihood of developing breast cancer (2). 
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The majority of these risk factors are unavoidable and cannot be modified, 
making prevention difficult. 
Because there is presently no primary prevention available for breast 
cancer, early detection and treatment are the best options for improving outcomes 
(3). The effect that delays in diagnosing and treating the disease have on survival 
remains controversial, as many studies have reported contradictory evidence. 
While some authors have found an improved survival rate for patients with 
shorter delays (4-15), other investigators have failed to find a difference (16-21), 
and one study has even reported better survival for patients with longer delays 
(22). However, research has tended to demonstrate that increased delay in the 
diagnosis and treatment of breast cancer can result in more advanced stages of the 
disease (3, 8, 11, 15, 23, 24). The stage (dependent on the size of tumor and 
whether it has spread) is widely recognized as the most important prognostic 
factor for breast cancer patients (15). Therefore, logically it should follow that 
delay can result in poorer chances for survival because of "stage drift" (15). This 
concept is based on the belief that tumors follow a time-dependent, linear 
progression through the different stages until metastasis occurs. The probability 
of successfully treating the disease decreases with later stage assessment (11, 15). 
There are many points in the process leading to treatment at which delay can 
occur and impact the outcome of the patient. 
There is a common series of events that leads to the definitive treatment 
(the initial surgery or drug treatment) of breast cancer (Figure 1) (25). The first 
stage is detection of an abnormality, which can occur through self-examination. 
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examination by a health care professional, or a screening mammogram. After a 
health care provider confirms that there is a change in the breast tissue or a 
suspicious finding, the patient is often referred to a specialist who can perform a 
fine-needle aspiration, a needle biopsy or a surgical biopsy to provide a definitive 
diagnosis. After diagnosis, the patient must consult with a specialist regarding 
appropriate treatment, decide which treatment to receive and book the first 
treatment. It is obvious, then, that there are numerous points in the care pathway 
at which the patient could experience a delay. The literature often divides these 
points into two phases of delay: patient delay and system delay. Patient delay is 
defined as the time interval between the patient first noticing a breast cancer 
symptom and first medical consultation (3, 26). System delay is the time interval 
from when the patient first presents to a health care provider to treatment, which 
is sometimes further divided into the period from first contact with a family 
physician to specialist referral, from referral to treatment, or from diagnosis to 
treatment (3, 26). 
Most studies examining the impact that delay has on survival and factors 
associated with increased waiting times have dealt with the patient delay interval. 
While studies have recently described baseline waiting time data for system delay, 
few studies have been conducted that look at factors that influence this waiting 
time (22, 27-32). The purpose of this study is to examine a portion of system 
delay and the factors associated with a prolonged delay during this time interval. 
Specifically, this study is designed to assess variation in the waiting times 
for Alberta breast cancer patients from definitive diagnosis to definitive treatment. 
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Determining this variation is very important for planning appropriate health 
services and ensuring equal access to these services. Selected factors (age, stage, 
Regional Health Authority, Regional Health Authority category, community size, 
and year of diagnosis) that might affect access to and utilization of breast health 
services will be analyzed to determine relationship to and degree of influence on 
the waiting period. Developing a better understanding of the factors and their 
impact on waiting times could result in the reduction of delays in cancer 
treatment, thereby improving health outcomes and reducing psychological 
morbidity that is imparted by anxiety during the waiting period. 
This thesis is divided into five chapters. Chapter Two provides a review 
of the literature, highlighting four areas of breast cancer research. First, it 
considers waiting times for various intervals in the care pathway. Secondly, the 
impact that delay has on survival of patients and the potential reasons for 
contradictory evidence are discussed. Finally, factors that are associated with a 
long patient and provider delay are presented. 
Chapter Three describes the objective of this study and specific research 
questions to be answered. It then discusses the data source, the quality and 
reliability of the data and the variables of interest. Finally it outlines the statistical 
methods employed to achieve the purpose of the study. 
Chapter Four presents the results of the analyses. It statistically describes 
the population and waiting time data for the period studied and for various 
subgroups. The regression model developed, the relative importance of predictors 
of waiting time and other significant findings are presented and discussed. 
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Chapter Five provides answers to the research questions and discusses 
relevant findings. Each variable examined is discussed and the results are 
compared to those indicated in the literature. The limitations and strengths of the 
study are also identified. Finally, conclusions and recommendations for future 
research are presented. 
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CHAPTER 2: A REVIEW OF THE LITERATURE 
2.1 Overview 
The literature reviewed for this study was obtained by various means, 
including computer-assisted searches using electronic databases (Medline, 
CINAHL, HKN, and CancerLit), the Internet, the Science Citation Index, and by 
consulting references used by relevant studies. 
There were four primary areas of breast cancer research that were 
reviewed: 1) reports of baseline data for care pathway waiting times; 2) the 
impact that delay has on survival of patients; 3) factors that are associated with a 
long patient delay and; 4) factors associated with a long system delay. This 
chapter will examine, evaluate, and integrate studies pertinent to each of these 
areas. 
2.2 Baseline Data on Waiting Times 
Expert groups have attempted to set standards of maximum acceptable 
waiting times between key events in the care pathway for cancer treatment (33-
36). The Canadian Society for Surgical Oncology (CSSO) has declared that no 
more than two weeks should transpire between the initial referral by a general 
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practitioner and consultation with a specialist or between diagnosis and initiation 
of treatment (33). The Canadian Association of Radiation Oncologists (CARO) 
has suggested that waiting for radiotherapy should not exceed 10 working days 
(34). The Canadian Strategy for Cancer Control (CSCC) set a four week goal for 
the interval between presentation of symptoms to a general practitioner and 
definitive diagnosis, while the National Health Service (NHS) in the United 
Kingdom (UK) set a two week goal for the period between referral and first 
outpatient appointment (35, 36). Furthermore, the NHS promised a maximum one 
month wait between diagnosis and treatment by 2001 and a maximum two month 
wait between urgent general practitioner referrals and treatment by 2002 for 
breast cancer patients (36). However, few recent studies have attempted to 
quantify actual waiting times for these key events. 
Adam et al conducted a study that examined the waiting times for three 
intervals: i) first suspicion of an abnormality to first general practitioner 
consultation, ii) general practitioner consultation to first visit with a surgeon and 
iii) first surgical visit to definitive treatment (37). More than a two week period 
for each interval was defined as a delay. This study utilized a structured interview 
to elicit key dates and information from 162 women with breast cancer between 
1978 and 1979 in London, England. They reported that 66 women (40.7%) were 
delayed at the first interval, 41 (25.3%) at the second interval and 57 (35.2%) at 
the third interval. Combining the data, 114 women (70.4%) experienced delay at 
some point before being treated for breast cancer. The authors concluded that 
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delay during the care pathway for breast cancer patients is a problem and needs 
attention. 
In a similar study based on structured interviews, Colbert looked at the 
waiting times between the referral by a general practitioner and first visit with a 
surgeon (38). The sample consisted of 62 women who had breast cancer between 
1991 and 1992 in North Wales or Wirral. The author found that only 21 women 
(34%) did not see a surgeon within two weeks of referral by a general practitioner 
and only 4 (6%) waited between six weeks and three months. Additionally, just 
17 women (26%) waited more than four weeks for surgery after the initial 
surgical consultation. Of greater concern, however, were the findings that 4 
women (6%) presented too late for surgery and 6 (10%) waited between three and 
nine months for a malignant diagnosis, which the author declared unacceptable. 
The results reported by Adam et al and Colbert could have been biased by 
patient memory and the truthfulness with which the dates were reported. The 
dates given by the patients during the interviews may not have been exact, with 
no way to ensure the accuracy of the reports. Furthermore, the samples in both 
studies were small, leading to problems with generalizing the results to other 
situations. Generalizability was more problematic in the Colbert study because 
the same oncologist treated the patients. In order to limit the selective recall bias 
and provide a larger scope of waiting times, more recent studies have used cancer 
registries and large data bases to provide baseline waiting time data (22, 27-32) 
(Tablel, Figure 2). 
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Table 1: A summary of studies that have reported baseline data for cancer care pathway waiting times. 
Author Year(s) 
Studied 
Country n Interval(s) Studied Median Waiting Period 
Mackillop et al 1982-1991 Canada 4971 definitive diagnosis to radiotherapy 61 days 
Caplan et al 1991-1995 USA 1659 i) clinical breast exam or 
mammogram to diagnosis 
ii) diagnosis to treatment initiation 
iii) abnormal screening result to 
treatment initiation 
i) 32 days 
ii) 10 days 
iii) 48 days 
Mayo et al 1992-1998 Canada 27515 first diagnostic procedure to surgical 
treatment 
34 days 
Olivotto et al 1996 Canada 13958 i) screening examination to first GP 
visit 
ii) screening examination to diagnosis 
i) 18 days 
ii) 26 days 
Sainsbury et al 1976-1995 UK 36222 i) referral by GP to first surgical visit 
ii) first specialist visit to definitive 
treatment 
i) 10 days in 1976,12 days in 1995 
ii) 7 days in 1976, 13 days in 1995 
Spurgeon et al 1997 UK 1517 i) referral by GP to first surgical visit 
ii) referral by GP to definitive 
treatment 
i) 9 days and 14 days for urgent and non-urgent 
cases, respectively 
ii) 27 days and 35 days for urgent and non­
urgent cases, respectively 
Simunovic et al* 2000 Canada 440 i) referral by GP to first surgical visit 
ii) first surgical visit to treatment 
decision 
iii) treatment decision to initiation of 
treatment 
iv) referral by GP to initiation of 
treatment 
i) 11 days 
ii) 0 days 
iii) 20 days 
iv) 37 days 
*This study did not look solely at breast cancer. 
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In a study that examined the time between diagnosis and commencement 
of radiation therapy in Ontario, Mackillop and colleagues found that the median 
waiting time for 4971 women was 61.5 days (27). This study included seven 
Ontario cancer centres and considered the years from 1982 to 1991. The authors 
reported that over the course of the 10 years, the number of patients who were 
treated within the recommended four weeks from referral steadily decreased. 
More alarming was the finding that the wait between completion of surgery and 
beginning of postoperative radiotherapy increased by nearly 103%. 
In a later Canadian study, Mayo et al also established that the wait for 
breast cancer treatment increased over time (29). This study looked at the number 
of days between the initiation of diagnostic procedures and surgical treatment for 
all women in Quebec with breast cancer between 1992 and 1998. For the entire 
time period, the median number of days for this interval was 34; however, it 
increased from 29 days in 1992 to 42 days in 1998. 
Caplan et al looked at the intervals from clinical breast exam to diagnosis, 
diagnosis to treatment initiation and abnormal screening result to treatment (28). 
All women who were screen tested through the National Breast and Cervical 
Cancer Early Detection Program in the United States during the years 1991-1995 
were included in this study. Median waiting times for the 1659 women were 
found to be 32 days, 10 days, and 48 days, for each interval respectively, 
suggesting that most women in this program received timely follow-up care after 
an abnormal screening examination. 
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A Canadian study that also looked at timeliness of follow-up after breast 
cancer screening for 15 342 women reported an even shorter median waiting 
period between screening examination and diagnosis than the American study (26 
days versus 32 days) (30). Ten percent of the women had to wait 79 days or more 
for their diagnosis after an abnormal screening result. 
Sainsbury et al evaluated the time elapsed from first visit to a general 
practitioner to first surgical visit and from first surgical visit to definitive 
treatment (22). This retrospective analysis of 36 222 breast cancer patients listed 
in the Yorkshire Cancer Registry between 1976 and 1995 indicated that the 
median delay from general practitioner referral to surgical visit had changed little 
over the years. On the other hand, median delay between surgical visit and 
treatment nearly doubled from seven days to 13 days during this same period of 
time. 
Spurgeon and colleagues looked at the waiting times between general 
practitioner referral to first surgical visit and between referral to definitive 
treatment for cancer patients in England in 1997 (31). Of the 13 454 patients 
studied, 1517 were breast cancer patients. The authors separately analyzed urgent 
and non-urgent referral cases. They reported that the median times to first 
surgical visit were nine and 14 days for urgent and non-urgent referrals, 
respectively. 
Simunovic et al also conducted a multi-cancer study examining the 
waiting periods from general practitioner referral to first surgical visit, first visit 
to treatment decision, treatment decision to treatment, and the total wait from 
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referral to treatment (32). The sample consisted of 1456 cancer patients in 
Ontario, with breast cancer being the most frequent diagnosis (n=440). The 
median times for the four intervals resulting from all of the cancer data were 11 
days, 0 days, 20 days, and 37 days, respectively. The surgeons who participated 
in the study deemed that 37.2% of the patients had to wait too long for surgery. 
Considering the CSSO recommendation that treatment should be started no more 
than two weeks after diagnosis, the authors were concerned that the median time 
was found to be 20 days and that only 32.5% of the cases met this guideline. 
Few of the studies reviewed reported baseline waiting times for the same 
intervals, making it difficult to compare them and to arrive at conclusions about 
the average time patients should expect to wait. Many of the authors expressed 
concern regarding the number of days some patients waited at various intervals in 
the care pathway. However, the following section demonstrates that there is no 
universal definition of what a delay is nor is there an agreement on the impact that 
delay has on prognosis. 
2.3 Impact of Delay on Survival 
Over the past 30 years numerous studies have examined the impact that 
patient and system delays have on the long-term survival of breast cancer patients 
(4-22). Controversy regarding this relationship is still prevalent because of the 
contradictory evidence reported by studies. The results from these studies can be 
divided into two categories: those reporting that extended delays reduce the 
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likelihood of long-term survival versus those reporting that lengthy delays do not 
impact long-term survival (Tables 2 and 3). 
The conflicting results may be accounted for by several factors, including 
differences in sample characteristics (e.g. which stages of cancer are included or 
the age cut-off); differences in the delay interval studied (e.g. patient vs. provider 
delay); differences in the definition of delay (e.g. 3 months vs. 9 months); and the 
point from which survival time was measured (e.g. first symptom, diagnosis or 
treatment) (15). The summaries of the studies presented in Tables 2 and 3 
demonstrate the array of methodological approaches. Given the differences in the 
studies, it is difficult to directly compare them; however, it is possible to evaluate 
them based on the aforementioned factors. 
Richards and colleagues conducted a systematic review in 1999 of 
observational studies that examined the association between the duration of 
symptoms and survival for breast cancer patients (14). This meta-analysis 
consisted of 87 studies between the years of 1939 and 1996 with a total of 
101 954 patients. The authors reported that the five-year survival rates (measured 
from date of diagnosis) were significantly lower for patients with longer patient 
delays (p<0.05). More specifically, those patients who delayed seeking help for 
three months or more had a 12% lower five-year survival than those with delays 
of less than three months and those with delays between three and six months had 
a 7% lower five-year survival rate. These results indicate that longer patient delay 
intervals are associated with lower survival rates. 
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Table 2: A summary of studies that indicate delay has a negative impact on the survival of breast cancer patients. 
Author Country n Sample 
Restrictions 
Setting of Data 
Collection 
Interval Studied Definition 
Of Delay 
Survival 
Measured 
From 
El wood and 
Moorehead 
Canada 1545 None Single site First symptom to diagnosis >12 months First symptom 
Feldman et al USA 664 None Multiple sites First symptom to first visit >3 months Diagnosis 
Charlson USA 685 None Single site First symptom to treatment >3 months Treatment 
Vernon USA 1983 None Single site First symptom to first visit >3 months Diagnosis 
Hainsworth et 
al 
Australia 548 None Single site First symptom to first visit >18 months First symptom 
and diagnosis 
Huguley et al USA 2093 None Multiple sites First symptom to first visit; 
First visit to diagnosis; 
First symptom to diagnosis 
>2 months Diagnosis 
Rossi et al Italy 189 None Single site First symptom to treatment >3 months N/A 
Rabinovich et 
al 
Argentina 1067 None Multiple sites First symptom to treatment >3 months Treatment 
Afzelius et al Denmark 7608 None Multiple sites First symptom to first visit; 
First visit to definitive surgery or 
biopsy 
>60 days Treatment 
Raabe et al Norway 2704 None Multiple sites First symptom to treatment >6 months Diagnosis 
Richards2 et al UK 2964 None Single site First symptom to first visit; 
First visit to treatment; 
Onset of symptoms to treatment 
>12 weeks First symptom 
and diagnosis 
Richards et al International 101954 None Meta-analysis Patient and 
Provider delay 
>3-6 months Diagnosis 
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Table 3: A summary of studies that indicate delay does not adversely affect survival of breast cancer patients. 
Author Country n Sample 
Restrictions 
Setting of 
Data 
Collection 
Interval 
Studied 
Definition of 
Delay 
Survival Measured 
From 
Alderson et al UK 258 Operable 
only* 
Single site First symptom to 
treatment 
Continuous 
variable 
Treatment 
Dennis et al USA 237 Operable 
only* 
Single site First symptom to first 
visit; 
First visit to treatment 
>3 months Treatment 
Wallgren et al Sweden 581 Operable 
only* 
<70 years 
Single site First symptom to first 
visit 
>3 months Treatment 
Fisher et al USA 1539 Operable 
only* 
Multiple sites First symptom to 
treatment 
>9 months Treatment 
Neave et al New 
Zealand 
1675 None* Population data First symptom to 
diagnosis 
>16 weeks Diagnosis 
Goodwin et al USA 188 >65 years** Population data First symptom to first 
visit 
>12 weeks Diagnosis 
Sainsbury et 
al 
UK 5708 None** Population data Referral to treatment >90 days Family-physician 
referral 
* Operable cancers are generally considered to be stage I and II. 
** All stages of cancer are included. 
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The findings of Richards et al are consistent with earlier studies (4-13). 
Feldman et al, Vernon et al, Hainsworth et al, Huguley et al, and Afzelius et al all 
examined the patient delay interval (5, 7, 8, 9, 12). Feldman et al studied 664 
patients with breast cancer in Brooklyn New York between 1975 and 1979 (5). 
The authors reported that patient delay was associated with poor survival for 
patients with aggressive (Class III) disease (P<0.001). In a study covering the 
same time frame as Feldman et al, Huguley and associates found that self-
examiners were more likely to have a short patient delay and a higher five-year 
survival rate (P<0.0001) (9). In their study of 10-year survival rates for 1983 
breast cancer patients, Vernon and colleagues reported that women with the least 
patient delay were more likely to survive (P<0.001) (7). An Australian study 
reported that patients who delayed presenting to their physician for 18 months or 
more had a significantly shorter five-year survival rate compared to those who 
presented earlier (42% versus 57%, p=0.03) (8). Afzelius et al determined that a 
short patient delay was associated with the longest survival (p<0.0001) (12). 
Patients who delayed presenting to a physician for more than 60 days had a 24% 
higher mortality rate than those who presented their symptoms earlier (p<0.0001). 
Charlson, Rossi et al, Rabinovich et al, and Raabe and Fossaa studied the 
impact of total delay on survival and also found that long delays were associated 
with reduced likelihood of survival (6, 10, 11, 13). Charlson studied survival 
measured from treatment for 685 women with breast cancer at the Yale-New 
Haven Hospital between 1962 and 1969 (6). Patients with total delays of less 
than three months had significantly better survival rates than those with longer 
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delays (p<0.001). The study of 189 patients with primary breast cancer also 
indicated a significantly lower three-year survival rate for patients with a lengthy 
total delay (p<0.05) (10). A Norwegian study of 2704 patients separated total 
delay into three subgroups: short delay (<2 months, n= 1075); delay (>= 2 months 
and <6 months, n=643); and long delay (>= 6 months, n= 467) (13). The five-
year survival rates for the three groups were 79%, 74% and 69%, respectively. 
The differences in survival rates between each group were significant (p<0.05). 
Similarly, Rabinovich et al divided total delay into three categories, but used three 
month intervals instead (11). Patients with a total delay of less than three months 
had statistically higher survival rates 10 years after treatment (p=0.029). 
A major limitation of the meta-analysis and the other studies was that they 
did not control for lead-time bias. Lead-time bias arises when survival is 
measured from the date of diagnosis because the interval between diagnosis and 
survival will be shorter for those whose diagnosis was delayed, regardless of the 
association between delay and survival (14, 15, 26). Therefore, to overcome the 
effect of lead-time bias on survival data, length of survival should ideally be 
measured from the onset of symptoms (4, 15, 26). Richards et al were unable to 
present such an analysis because of missing data; however, Elwood and 
Moorehead and Richards 2 et al have conducted studies that did account for lead-
time bias (4, 8, 15). 
Elwood and Moorehead conducted a secondary data analysis that 
examined the influence of delay on survival for a population of 1545 breast 
cancer patients (4). They studied the interval from the first recorded symptom to 
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diagnosis and survival was measured from both the onset of symptom(s) and 
diagnosis. The authors reported that when survival was measured from the time 
of diagnosis, patients with a long delay (>12 months) had a 13% lower five-year 
survival rate than those with a shorter delay (p<0.0001) and when measured from 
onset of symptoms those with a long delay continued to show a significantly-
lower long-term survival (p<0.001). As a result, lead-time bias did not account 
for their conclusions and the results support the Richards et al finding that shorter 
delays do improve survival. Similarly, Richards 2 et al measured survival from 
both the date of diagnosis and the onset of symptoms (15). Delay was defined as 
the time from first symptom to first consultation with a medical professional. The 
data for the 2964 patients indicated that a long delay (>12 weeks) was associated 
with worse survival when survival was measured from both diagnosis (p<0.001) 
and onset of symptoms (p<0.003). 
Although very few studies assess the impact of delay on survival from the 
onset of symptoms, the studies by Elwood and Moorehead and Richards 2 et al are 
important to consider (4, 8, 15). These studies provide evidence that lead-time 
bias may not be responsible for the long-term survival differences between long 
and short delay groups as noted by those studies that do not measure survival 
from symptom onset (5-7, 9-14). Others would argue that the results are sensitive 
to the patients' reports of onset of symptoms (26). The accuracy of the date of 
symptom onset cannot be verified and is influenced by the reliability of the 
patient's memory and the accuracy with which they report the date. If the date of 
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symptom onset is inaccurate, any subsequent analysis is subject to the bias (22, 
26). 
A second bias that may have influenced the results of the meta-analysis by 
Richards et al was their inability to include the study by Sainsbury and colleagues 
(22). Sainsbury et al conducted a population retrospective analysis of 36 222 
breast cancer patients in the UK. This was the only study reviewed that measured 
survival from general practitioner referral and defined delay as the interval 
between referral and treatment (a component of provider delay). The authors 
found no evidence that long provider delays (>90 days) adversely impacted long-
term survival. In fact, Sainsbury et al established that short provider delays (<30 
days) were associated with poorer survival (p<0.001). 
Correspondingly, in a study of 188 breast cancer patients older than 65 
years of age, Goodwin et al found no adverse impact of patient delay on 10-year 
survival (21). In their evaluation of 549 breast cancer patients, Hainsworth et al 
found that patients who delayed seeking medical help for six months or more did 
not have a lower five-year survival rate compared to those who presented their 
symptoms to physicians within six months of discovery (8). Dennis and 
associates also examined the influence that patient delay has on survival and 
reported that delay did not predict survival (17). This study only included 
operable stage breast cancer patients, as did Alderson et al, Wallgren et al and 
Fisher et al (16, 18, 19). Two of these studies examined the interval from first 
symptom to treatment, while the other looked at time elapsed between first 
symptom and first medical consultation. These restricted sample studies all found 
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no significant relationship between delay and long-term survival. Although 
Feldman et al found that patients with aggressive disease who delayed were 
significantly less likely to survive, a separate analysis of patients with operable 
cancer did not support this relationship (5). A delay from symptom recognition to 
diagnosis was not found to influence survival by Neave et al in their study of 
1675 breast cancer patients (20). 
The phenotypic traits of the tumor could account for the contradictory 
evidence reported by Sainsbury et al and the other studies (26). Patients with 
phenotypically aggressive tumors may detect symptoms earlier and experience 
more severe symptoms causing them to seek medical advice earlier and 
physicians to react quicker (26). Because aggressive tumors would inherently 
predispose patients to worse outcomes, it would appear that those with short 
delays had a lower long-term survival (26). This is supported by Feldman et al's 
findings that survival was reduced by delay for patients with aggressive tumors, 
whereas this relationship did not hold true for patients with less aggressive disease 
(5). Further support is provided by the examination of survival for 160 women 
with breast cancer by Cummings et al (39). Results showed that the relationship 
between delay and long-term survival depended on the rate of tumor growth: 
patients with slow growing tumors who delayed had a shorter survival time, 
whereas the survival of patients with fast growing tumors was not affected by 
delay. Coates suggests that the impact of this bias is different for patient and 
provider delay (26). Afzelius et al supported this suggestion by reporting that 
longer provider delays were associated with improved outcomes, whereas longer 
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patient delays were associated with poorer outcomes (12). Therefore, it is 
possible to attribute the reduced survival with decreased provider delay, reported 
by Sainsbury and colleagues, to samples with more aggressive phenotypic traits 
and the ability of physicians to discern urgent cases and refer them faster. 
With the exception of the Sainsbury et at study, the studies that reported 
that long delays do not negatively impact survival could be criticized on the basis 
of their sample inclusion criteria (16-21). These studies all included sample 
restrictions, whereas those studies that reported that delay lowers long-term 
survival had no sample restrictions (Tables 2 and 3). Alderson et al, Dennis et al, 
Wallgren et al, and Fisher et al restricted their samples to those patients with 
operable breast cancer only (generally stage I and II cancers) (16-19). Several 
studies have reported that within individual stages, longer delays have no adverse 
impact on survival, but when all stages are considered together delay does 
influence survival (4, 11, 15). Therefore, restricting the sample to stages I and II 
could reduce the chance that a survival difference would be observed. 
In conclusion, those studies that have reported a negative association 
between delay and survival are, as a whole, more numerous and based on broader 
sample inclusion criteria. The results from these studies suggest that it is 
important to monitor waiting times at all intervals of the care pathway to ensure 
that patients' prognosis is not affected by long delays. Reduction of waiting times 
is one of the few means presently available in the fight against breast cancer 
mortality. Awareness of factors that contribute to delays could help prevent 
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unnecessary delays and the possible negative impact on survival. The following 
section will examine determinants of patient delay. 
2.4 Factors Associated With Patient Delay 
Delay by the patient is the interval from first symptom recognition to first 
medical consultation. Several studies have examined what causes patients to 
delay in presenting breast symptoms to a physician. Commonly studied variables 
include age, breast symptom and socioeconomic status, whereas education, ethnic 
origin, marital status, and family history have been studied to a lesser extent 
(Table 4). 
Two problems arise when studying this component of delay. First, most 
studies obtain information and dates by interviewing the patients after a new 
diagnosis of cancer. The reliability and validity of the data are subject to recall 
bias of symptom recognition and the tendency to underreport the length of delay 
(40). It would follow then, that there is likely more patient delay than what is 
reported in the literature (40). Secondly, patient delay and provider delay are not 
mutually exclusive. The total time elapsed from symptom recognition to 
consultation might be increased if the patient has difficulty obtaining an 
appointment, which is attributable to the provider (3). However, the separate 
assessment of such cases is extremely difficult. 
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Table 4: A summary of studies that support or refute factors that are predictive of long patient delay. 
Predictive Factor Supporting Studies Refuting Studies 
Age Antonovsky and Hart man* Arndt et al (n=287) 
Afzelius et al (n=7608) Coates et al (n= 1470) 
Hainsworth et al (n= 548) Nichols et al (n=582) 
Ramirez et al* Richards2 et al (n=2964) 
Richardson et al (n=28 486) 
Schottenfield and Robbins (n=7000+) 
Adam et al (n=162) Burgess et al (n=185) 
GIVIO (n=l 110) 
Gould-Martin et al (n=274) Menon et al (n=359) 
Mor et al (n=214) Rossi et al (n= 189) 
Absence of a breast lump Burgess et al (n=185) Coates et al (n=735) 
Feldman et al (n=622) Gould-Martin et al (n=274) 
MacArthur and Smith (n=145) Nichols et al (n=582) 
Adam et al (n=162) Arndt et al (n=287) 
Moretal(n=214) Rossi etal (n=189) 
Low Socioeconomic 
Status 
Antonovsky and Hartman* Coates et al (n=735) 
Gould-Martin et al (n=274) Richardson et al (n=28 486) 
Samet et al (n=780) 
Burgess et al (n=185) Mor et al (n=214) 
Ramirez et al* 
Less Education Antonovsky and Hartman* Coates et al (n=735) 
Ramirez et al* 
Arndt et al 01=287) Mor et al (n=214) 
Samet et al (n=780) 
Non-White Ethnic Origin Coates et al (n=735) Ramirez et al* 
Richardson et al (n=28 486) Vernon et al (n=1983) 
Samet et al (n=780) Dennis et al (n=237) 
Unmarried Arndt et al (n=287) Burgess et al 01=185) 
Mor et al (n=214) Neal et al (n=810) 
Ramirez et al* 
Richards2 et al (n=2964) 
No Family Personal 
History of Breast Disease 
Arndt et al (n=287) Burgess et al (n=185) 
Gould-Martin et al (n=274) Samet et al (n=780) 
* Literature Review 
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2.4.1 Age 
The most commonly studied variable for impact on patient delay is age. 
In a systematic review of the literature that looked at risk factors predicting 
patient delay, Ramirez et al included 19 papers in their assessment (41). The 
authors concluded that the strongest determinant of patient delay was older age. 
That is, older patients waited longer to present their symptoms to a physician. 
Antonovsky and Hartman performed a review of the literature prior to 1974, and 
also reported that older age was commonly associated with a longer patient delay 
(40). A recent German study reaffirmed the strong association between older age 
and longer patient delay (P=0.01) (42). Patients over the age of 50 were three 
times as likely to delay seeking medical care for three months or more compared 
to women under 50 (24.7% versus 7.1%). Hainsworth et al also reported that 
delay (defined as more than six months) was associated with older age (median of 
68 versus 65 years, p=0.042) (8). In a large London study of 2964 patients 
between 1975 and 1990, Richards 2 et al determined that patients older than 65 
years had longer symptom duration (P<0.0001) (15). Similarly, in their study of 
new breast cancer patients, Nichols et al reported that women over 65 had an 
increased patient delay as well as more malignancies (43). The increased 
frequency of malignancies in this age group led the authors to speculate that age 
and diagnosis might not separately influence patient delay. Schottenfield and 
Robbins studied more than 7000 breast cancer patients during two separate time 
periods, 1949-55 and 1956-62 (44). They found that older women (>65 years) in 
both periods were more likely to delay in seeking medical care. During 1949-55 
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54% of women under 65 years were seen within three months of first symptom 
recognition, whereas only 48% of those older than 65 years were. During 1956-
62, 58% of younger women versus 52% of older women were seen within three 
months. Afzelius and colleagues performed a study on patients with primary 
breast cancer who were registered in the Danish Breast Cancer Cooperative 
Group treatment programs between August 1977 and November 1982 (12). The 
results from the 7608 patients studied indicated that younger (<40 years) patients 
presented their symptoms to a physician significantly sooner than did older 
patients (>40 years). The median duration between first symptom recognition and 
first consultation with a physician was 10 days for younger women compared to 
20 days for older women (p<0.0001). 
Two studies have found the reverse relationship between age and patient 
delay. Richardson and associates examined the association between age and 
patient delay for 28 486 women with breast cancer in Los Angeles County 
between 1977 and 1985 (24). The authors found that older patients presented 
their symptoms to a physician sooner than younger women did (trend P<0.001). 
In their study of 1470 newly diagnosed breast cancer patients, Coates and 
colleagues established that younger women (<40 years) were more likely to delay 
consultation (p<0.01) (45). 
Several studies have failed to find an association between age and patient 
delay. Burgess et al studied 185 women with breast cancer from the United 
Kingdom between 1992 and 1994 (46). They reported that age was not 
significantly associated with extent of patient delay (P=0.1). In their examination 
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of 1110 newly diagnosed breast cancer patients from 63 Italian hospitals, GIVIO 
indicated that no difference in patient delay was found between ages (23). Adam 
and colleagues performed a study with 162 women with breast cancer (37). 
Again, age was not found to influence patient delay. Gould-Martin et al 
examined 274 women in the Los Angeles County between 1967 and 1977 (47). 
The authors defined delay by a patient as greater than two weeks from detection 
of a symptom to presentation to a physician. No association between this delay 
and age of patient was found. In their assessment of 189 women in Rome, Rossi 
et al did not find that age influenced patient delay (10). Similarly, in the study of 
359 Asian women performed by Menon et al, age was not found to be a 
determinant of patient delay (48). Although 16.5% of older patients (>35 years) 
compared to only 6.5% of younger women (<35 years) waited more than a year to 
present their symptoms, no significant association was found. Mor et al divided 
their sample of 214 breast cancer patients into those younger than 45 years and 45 
years and older (49). They reported that age was not a predictor of delay. Samet 
and associates studied 780 patients with newly diagnosed cancer, including those 
with cancer of the breast (50). Age was not found to influence patient delay; 
however, this sample only consisted of patients older than 65 years. In previously 
mentioned studies by Richards 2 et al and Nichols et al that did find an association 
between patient delay and age, it was women over the age of 65 who delayed 
significantly more (15, 43). Therefore the exclusion of patients under the age of 
65 could account for lack of association found by Samet et al. 
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Close examination of Table 4 reveals a pattern in the number of 
individuals in the studies (n) that did and did not support the idea that age 
influences patient delay. Those studies where age was reported to be a predictive 
factor generally had larger sample sizes than studies that did not find an 
association. Only two studies that did report a difference in waiting times were 
based on samples of less than 1000 patients, whereas only one study that did not 
report a difference was based on a sample of this size or larger. The small 
samples of the studies could account for their inability to find an association 
between age and patient delay. This is due to the direct relationship between 
sample size and power of the statistical analysis. Power is a measure of the 
sensitivity of the analysis to detect an effect of the independent variable (i.e., an 
effect of age on patient delay) (51). The larger the power of the experiment the 
more likely an effect will be reported. Therefore, studies with larger sample sizes 
have a greater power to determine an association between age and patient delay. 
On the other hand, it is easy to find a statistically significant difference with large 
sample sizes even if the difference is not large enough to be clinically useful. It is 
important in these cases to also examine the clinical significance of the 
statistically significant results because the size of the difference may not be large 
enough to justify a change in clinical practice. 
2.4.2 Breast Symptom 
The influence that the symptom(s) discovered by women has on patient 
delay has also been evaluated by several studies. In a study of 162 women with 
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breast cancer, 70.4% of the women indicated that their presenting symptom was a 
painless lump, while 29.6% reported other symptoms, including a painful lump, 
breast pain and changed appearance of the breast (37). Although the authors 
indicated that symptoms other than a lump did lead to increased patient delay, the 
impact was not statistically significant. Arndt et al evaluated 287 women with 
newly diagnosed breast cancer and reported that patients who noticed a lump had 
somewhat shorter delays, but again this relationship was not significant (P=0.24) 
(42). Rossi and associates also reported that symptom at presentation was not a 
determinant of patient delay for their sample of 189 breast cancer patients (10). 
Although Mor et al found that patients who reported a lump were significantly 
more likely to think that they had breast cancer (p<0.05), they were not less likely 
to delay presenting their symptom to a physician (49). 
While these studies reported no association, other studies have found the 
presenting symptom to be a significant predictor of patient delay. MacArthur and 
Smith studied 145 women with breast cancer from four hospitals in the UK (52). 
They divided initial symptom recognized by the women into three categories: a 
lump on its own; a lump together with another symptom(s); or another symptom 
without a lump. Those women who had a lump or a lump and another symptom 
were found to have similar delay patterns (median of 28.5 days versus 26 days, 
respectively). Therefore, the authors grouped the women with a lump together for 
the analysis of symptom impact on patient delay. Women who did not initially 
discover a lump were significantly more likely to delay in consulting a physician 
than those who had found a lump (p=0.0262). Of the 35 women who did not 
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initially discover a lump, 11 noticed one later. These women were separately 
analyzed from those who never found a lump and were found to have 
significantly different delay times (median of 56 days versus 86 days, 
respectively). MacArthur and Smith concluded that it is the absence of a lump, 
rather than the presence of another symptom that is important in predicting delay. 
They speculated that this difference in waiting times is the result of the focus of 
breast health public education on the classical symptom of the painless lump. In 
their study of 622 breast cancer cases, Feldman et al found that patients with 
symptoms other than a breast lump had significantly longer patient delay periods 
(P<0.01) (5). Burgess et al found that women with no breast lump were four 
times more likely to delay seeking medical attention for 12 weeks or more than 
those who had a lump (41% versus 10% of sample, respectively, P<0.0001) (46). 
Nichols and associates reported that in women older than 65 years, patient delay 
was associated with symptoms other than a lump, but the sample was too small to 
compare statistically (43). Coates et al reported that the absence of a lump was a 
significant determinant of patient delay for their sample of 735 women (P<0.04) 
(45). In their assessment of patient delay for 274 women, Gould-Martin and 
colleagues found that the most significant factor influencing delay was the type of 
initial symptom (47). Those women with a lump consulted a physician within a 
median of seven days, whereas those without a lump waited a median of 31 days 
(P<0.001). 
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2.4.3 Socioeconomic Status 
A third common variable which has been studied regarding its Impact on 
patient delay is socioeconomic status (SES). In their systematic review of 19 
papers, Ramirez et al found that there was insufficient evidence to support their 
hypothesis that a lower SES led to increased delay by patients (41). Burgess et al 
studied 185 women who attended a breast unit in London (46). The authors found 
that SES was not significantly associated with patient delay (P=0.3). In their 
study of 214 newly diagnosed breast cancer patients from nine Rhode Island 
hospitals between 1984 and 1986, Mor et al reported that SES was not a predictor 
of delay (49). 
When no association between the independent variable (SES) and the 
dependent variable (patient delay) is reported, it is important to consider the 
statistical power of the study. The small samples utilized by Burgess et al and 
Mor et al reduce the power to detect an effect of SES on patient delay and could 
account for their failure to determine SES as a predictive factor of delay (51). 
Those studies that did find an association between age and patient delay were 
based on larger samples, providing more power to their analyses (Table 4). 
Antonovsky and Hartman concluded from their literature review that low 
SES was commonly associated with patients who delayed (40). In their 
assessments of the influence of SES on patient delay, Richardson et al and Coates 
et al both reported that delay increased with decreasing SES (trend P<0.001 and 
trend P<0.04, respectively) (24,45). Gould-Martin et al found that patients with a 
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high SES had a median delay of 7 days, while those with a low SES had a median 
delay of 14 days (P<0.1) (47). 
Samet et al did not specifically examine SES (50). However, they did look 
at the impact of income- a variable used in determining SES- on patient delay. 
They reported that mean annual income declined with increasing breast cancer 
patient delay (p<0.05). 
2.4.4 Education 
Although education can be used in SES classification, several studies 
have looked independently at the association between education and patient delay. 
Ramirez and colleagues indicated that there was moderate evidence from their 
systematic review of the literature that fewer years of education was associated 
with an increased patient delay (41). The literature review performed by 
Antonovsky and Hartman yielded the same conclusion that less education is a 
determinant of delay for breast cancer patients (40). Coates et al reported from 
their study of 735 women that those with more education waited less to present 
their symptoms (trend P<0.04) (45). However, three studies failed to determine 
that education was associated with patient delay (42,49, 50). 
2.4.5 Ethnic Origin 
Given the discrepancy in breast cancer survival between white and non-
white women, several studies have examined the impact of race on patient delay 
in an attempt to explain the prognosis difference. Ramirez et al hypothesized that 
33 
being of non-white origin was a predictor of patient delay (41). Their literature 
review offered what the authors deemed to be moderate evidence for this 
hypothesis. Richardson and colleagues studied 23 567 non-Hispanic Whites, 
2539 Blacks and 2380 Hispanics from the Los Angeles County (24). Both the 
Hispanic and the Blacks were at greater risk of long patient delay compared to 
non-Hispanic Whites (P<0.001 and P<0.001, respectively). In the study of 1983 
women from Texas, Vernon et al also divided their sample into White, Black and 
Hispanic women (7). Whites were more likely to see a physician within two 
months of noticing symptoms than were non-Whites (P<0.001). This difference 
was more pronounced between White and Black women than it was for White and 
Hispanic women. Coates et al, Samet et al and Dennis et al only divided their 
samples into two race categories (45, 50, 17). Coates and associates reviewed 410 
Black and 325 White women (45). The authors found the median symptom 
duration was longer for Black women than for White women, bordering on 
significance (16 days versus 14 days, P=0.06). Samet et al reported that the 
difference in waiting time for Hispanics and non-Hispanics was not statistically 
significant (50). Dennis et al found no correlation between race (White or Black) 
and patient delay for 237 breast cancer patients (17). The small sample used by 
Burgess et al and the reduced power of the analysis could account for the reported 
lack of association between race and delay (51). 
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2.4.6 Marital Status 
The marital status of women has also been examined for its influence on 
the patient delay interval. Prior to their literature review, Ramirez and colleagues 
hypothesized that being unmarried would increase the patient delay period (41). 
All articles included in the review regarding this association refuted their 
hypothesis. In their study of 287 women with breast cancer in Germany, Arndt et 
al failed to find a relationship between marital status and patient delay (P=0.13) 
(42). Neale et al studied 810 married and 320 widowed white women with breast 
cancer (53). The authors reported that 56.1% of married women and 55.6% of 
widowed women visited a physician within three months of symptom detection, 
resulting in a non-significant relationship between marital status and patient 
delay. Richards 2 et al's study was based on a sample of 2964 patients, 81.1% of 
which were married (15). No association between marital status and duration of 
patient delay was established. Burgess et al and Mor et al also failed to uncover 
an association between marital status and patient delay (46,49). 
2.4.7 Family History and Previous Breast Disease 
One might speculate that women who have a family history of breast 
cancer or who had benign breast health problems themselves might be more 
aware of the problem and present to their physicians sooner than women with no 
past experience with breast disease. However, most of the studies that have 
examined this association have found no evidence to support this speculation. 
Burgess et al examined the impact of previous experience with cancer in family or 
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friends on the patient delay period, but found no significant difference between 
those with a history and those without one (P=0.8) (46). Samet and colleagues 
also found that a family history of cancer was not associated with decreased 
patient delay (50). Gould-Martin et al separately examined the impact of family 
history and a history of benign breast disease on patient delay (47). The authors 
reported that family history was not predictive of delay; however, they did find 
that women with past benign breast disease waited longer to consult a physician 
(P<0.1). An examination of breast cancer patients in Germany found an 
association between women with previous benign disease and long patient delay, 
but no relationship between family history and delay was identified (42). The 
authors suggested that patients with a previous benign breast disease waited 
longer to present to a physician because they attributed the new symptoms to their 
benign breast disease. Burgess et al reported that four of the 66 women (6%) who 
delayed consulting a physician indicated that they delayed because they attributed 
their symptom(s) to previous benign breast disease (46). 
Numerous factors that could impact patient delay have been reviewed, 
including age, presenting symptom, socioeconomic status, education, ethnic 
origin, marital status, and past experience with a breast disease. Age has been the 
most commonly studied variable. There is considerable evidence that younger 
patients are less inclined to wait to present their symptoms to a physician. Most 
studies that did not support this connection had reduced power to demonstrate an 
association because of the small samples the studies were based on. The 
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existence of a lump as a presenting symptom also seems to reduce the patient 
delay interval. This could be accounted for by women's increased awareness of a 
lump as a breast cancer symptom because of public health education campaigns 
focusing on breast-self examinations for early lump discovery. The idea that 
patients of low SES experience more delay was substantiated by most of the 
studies examining this factor. Factors related to SES that were independently 
studied were education and ethnic origin. Being non-White seemed to increase 
the patient delay interval; however, education was not found to be associated with 
delay. The few studies that looked at marital status and family or personal history 
of breast cancer did not provide support that delay is impacted by these factors. 
Determinants of system delay have been studied much less extensively than those 
of patient delay. These factors are reviewed in the following section. 
2.5 Factors Associated With System Delay 
System delay is the interval from first medical consultation to treatment. 
Unlike patient delay, the system component is often further subdivided into the 
period from first consultation to referral to a specialist, the period from referral to 
treatment, and even smaller intervals of delay (26). Variables that could impact 
provider delay that have been examined include: age, breast symptom, diagnosis, 
ethnic origin, administrative problems, family history, and region (Table 5). 
Aside from these variables, increased delay might be attributable to the patient if 
she cancels or misses an appointment or chooses a later one. It is difficult to 
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Table 5: A summary of studies that support or refute factors that are predictive of long provider delay. 
Predictive Factor Supporting Studies Refuting Studies 
Age Afzelius et al (n=7609) 
Caplan et al (n=1659) 
Finley and Francis (n=454) 
Sainsbury et al (n=18 846) 
Burgess et al (n=185) 
Caplan et al (n=996) 
Ramirez et al* 
Adamet al (n=162) 
Dennis et al (n=237) 
Absence of a breast lump Adam et al (n=162) 
Caplan et al (n=1659) 
Ramirez et al* 
Burgess et al (n=185) 
Caplan et al (n=996) 
Adam et al (n=162) 
MacAtthur and Smith (n=145) 
Diagnosis By waters (n=180) 
Nichols et al (n=582) 
Greer (n=157) 
Olivotto et al (n=13 958) 
Ethnic Origin/Race Caplan et al (n=1659) Dennis et al (n=237) Caplan2 et al (n=996) 
Ramirez et al* 
Administrative Problems Adam et al (n= 162) 
No Family or Personal 
History of Breast Disease 
Finley and Francis (n=454) Adam etal(n= 162) 
Region Caplan et al (n=1659) 
Mackillop et al (n=18 077) 
Spurgeon et al (n=1517) 
Caplan et al (n=996) 
Olivotto et al (n=13 958) 
*Literature Review 
determine cases when this occurs and completely separate and analyze delay 
attributable only to the system. 
2.5.1 Age 
Age is the most frequently examined factor of system delay. Two 
arguments can be made regarding the impact that age has on delay. First, it is 
possible that older patients will experience more provider delay because 
physicians will not feel it necessary to quickly treat them based on their longevity. 
On the other hand, younger women might be delayed more because physicians 
will regard them as low risk for breast cancer. The latter association has been 
reported by several studies. 
The systematic review conducted by Ramirez et al yielded strong 
evidence for their hypothesis that younger age is a risk factor for provider delay 
(41). They found that four of the five articles reported this association between 
age and provider delay, consisting of a total sample of 5146 patients, whereas the 
non-supporting paper had a sample of 200 patients. Caplan 2 and colleagues 
studied the interval between diagnosis and treatment for 996 breast cancer 
patients between 1985 and 1986 (54). The authors reported that younger age was 
significantly associated with longer treatment intervals (trend p<0.001). This 
association countered their hypothesis that older women would experience more 
delay because the system would not feel obliged to evaluate and treat older 
women aggressively. In a later study by Caplan et al, younger age (<70 years) 
was also found to be predictive of treatment delay (p=0.035) for the 1659 women 
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studied (28). Burgess and colleagues examined general practitioner delay for 185 
women with breast cancer (46). General practitioner delay was defined as the 
interval from first contact with a physician to subsequent referral to a specialist. 
Again, compared to older patients, younger patients were more likely to 
experience delay (mean of 55 versus 49 days, respectively, P=0.01). Finley and 
Francis and Afzelius et al also looked at the influence of age on physician delay, 
but defined this period as the time between first contact and biopsy or treatment, 
rather than referral (55, 12). Both studies reported significant trends in the 
negative association between age and physician delay (p=0.03 and p<0.0001). In 
their study, Sainsbury et al examined the interval from referral to treatment for 18 
846 patients with breast cancer (22). Overall, 48% (2061) of those patients 
younger than 50 years received their treatment within 30 days of family-physician 
referral, compared with 64% (9313) of patients older than 50 years (p<0.001). 
Furthermore, 90 days after referral, 8% of younger patients compared to 3% of 
older women still had not been referred (p<0.001). The authors concluded that 
this negative relationship between age and system delay was due to physicians 
being more suspicious of breast cancer in older women and referring them to a 
specialist faster. 
Two studies did not confirm that younger age predicted system delay (17, 
32). One of these studies evaluated the waiting times for the intervals from 
referral to first visit to a surgeon, first surgical visit to treatment decision and from 
treatment decision to surgery for eight regional cancer centres in Ontario (32). 
The duration of each interval was not significantly impacted by patient age. 
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2.5.2 Breast Symptom 
The breast symptom that the patient presents to a physician might impact 
system delay. The hypothesis that presenting to a physician with a symptom other 
than a lump is predictive of system delay was strongly supported by all of the 
pertinent articles reviewed by Ramirez et al (total of 1476 patients) (41). In a 
study of 185 women with breast cancer, referral delay by the general practitioner 
was significantly associated with symptoms other than a lump (P=0.002) (46). 
The women who presented with no lump were three times more likely to be 
delayed than those who had a lump. Adam et al examined the interval from first 
contact with a general practitioner to outpatient appointment for 162 women with 
newly diagnosed breast cancer (37). The failure of the general practitioner to 
attribute the symptom to breast cancer was the most common reason for delay, 
occurring in 46.3% of the sample. Caplan and associates determined that for 
White and Black women, the presence of a lump was associated with shorter 
system delay (defined as interval from first physician contact to definitive 
diagnosis) compared to other symptoms; however, symptomatic women tended to 
have shorter system delays than asymptomatic women (mean of 10.7 days versus 
89.3 days) (54). The authors attributed the noted relationship between a shorter 
system delay and presence of a lump to the commonality of the painless lump as a 
recognized breast cancer symptom by physicians, which expedites their response. 
A later study by Caplan et al also indicated that women with breast cancer 
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symptoms had a significantly shorter delay interval from abnormal mammogram 
to treatment than those with no symptoms (p=0.013) (28). 
MacArthur and Smith independently looked at two phases of system 
delay: from first medical contact to referral for specialist opinion; and from 
referral to definitive treatment (52). Within two days of first visit, 89.5% of 
patients with a lump and 85.5% with a lump and other symptom were referred 
compared to only 42% of those without a lump (p=0.0001). However, delay from 
referral to treatment was not significantly affected by the symptom. Adam et al 
found no significant association between length of various system delay intervals 
and different symptoms (37). 
2.5.3 Diagnosis 
One might expect that patients with malignant disease of the breast to 
experience shorter system delays than those with benign breast diseases. Few 
studies have looked at this association. In a recent study of seven provincial 
screening programs, Olivotto et al reported that women found to have breast 
cancer had shorter times to diagnosis than did women whose biopsy indicated 
benign disease (30). Nichols et al studied doctor delay (interval from first 
physician consultation to referral to surgical unit) and hospital delay (referral to 
outpatient attendance at surgical unit) (43). Both of these intervals were 
significantly reduced in malignant cases. The median length of doctor delay was 
one day for malignant cases and four days for benign cases (P<0.10). The median 
hospital delay was nine days for malignant cases and 13 days for benign cases 
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(P<0.005). The authors concluded that physicians were generally able to 
distinguish between malignant and benign breast disease at first contact. 
Bywaters noted that on average patients with breast cancer had a biopsy four 
times as fast as those with benign conditions (10.1 days versus 40.9 days) (56). 
Greer found that 19% of malignant cases compared to 24 % of benign cases were 
delayed more than five weeks from first consultation to biopsy (57). This result 
was not significant. 
2.5.4 Ethnic Origin/Race 
Few studies have assessed the impact of ethnicity on system delay. 
Ramirez et al hypothesized that being of non-White ethnic origin would increase 
system delay (41). However, their review of the literature provided moderate 
evidence against this hypothesis. Caplan 2 et al's study of 477 White and 519 
Black patients with breast cancer also yielded no relationship between race and 
system delay (54). 
While these studies indicated that ethnic origin is not a determinant of 
system delay, two other studies have found a relationship. Caplan and colleagues 
studied the diagnostic interval (time from abnormal screening to diagnosis), 
treatment interval (time from diagnosis to treatment initiation) and total delay 
interval (time from abnormal screening to treatment initiation) (28). The sample 
consisted of 1659 women of various ethnic origins, including white (n=975), 
Black (n=255), Hispanic (n=270), Asian (n=45), American Indian/Alaskan Native 
(n=97), and other/unknown (n=17), who were part of the National Breast and 
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Cervical Cancer Early Detection Program (NBCCEDP) between 1991 and 1995. 
Compared to all other races, white patients had significantly shorter diagnostic 
delay (median of 29 days versus 34.2 days, respectively, P<0.0001). Significantly 
shorter treatment and total delay was also experienced by white patients compared 
to all other race and ethnic groups (P<0.004, P<0.0001, respectively). Dennis et 
al reported that the interval from first medical consultation to treatment was 
greater for Black patients, however, no significance values were reported (17). 
2.5.5 Administrative Problems 
Administrative problems include factors that contribute to delay that are 
not attributable in any way to the patient or her characteristics, including 
appointments, beds, rescheduling because of physician absence and missed 
diagnoses. Delay between general practitioner and outpatient appointment and 
between outpatient appointment and definitive treatment for 162 patients was 
examined by Adam et al (37). The second most common reason for delay in 
receiving a surgical visit was a problem in obtaining an appointment. This 
difficulty occurred for 36.6% of patients. Delay in treatment was most commonly 
the result of other administrative problems, including waiting for a hospital bed, 
the inability of the physician to offer a definitive diagnosis and the selection of 
treatment. 
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2.5.6 Family History and Previous Breast Disease 
A patient with a personal or family history of breast problems could be 
perceived as high risk by providers and experience less delay. In a study of 454 
breast cancer patients in the United States, Finley and Francis examined factors 
associated with physician delay (55). This interval was considered the time 
elapsed from first contact with a physician to a biopsy and a delay was defined as 
more than 30 days for this period. A family history of breast cancer was positively 
associated with physician delay (p=0.03), however, a personal history of breast 
cancer was not. Adam et al reported that no component of system delay was 
influenced by whether or not the woman had a positive family history of breast 
cancer (37). 
2.5.7 Region 
Centralization of specialty services could impact the waiting times of 
patients who live far and close to the treatment centre. Spurgeon et al examined 
waiting times for cancer patients in England after a referral from a general 
practitioner to first surgical visit and definitive treatment (31). Breast cancer was 
the most frequent type of cancer in the sample (n=1517). The authors indicated 
that there was significant variation in patients' waiting times according to where 
the treatment was provided. Two American studies have also shown that regional 
variation exists in the system delay waiting period (28, 54). One of these studies 
also showed that delay was shorter for rural than for urban women (p=0.002) (28). 
The time to receive a diagnosis after an abnormal screening examination for 
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13 958 women across screening programs in Canada was shown to vary 
considerably between programs (30). Mackillop et al studied the interval between 
diagnosis and initiation of radiation treatment for all patients receiving primary 
radiotherapy for carcinoma of the larynx, cervix, lung, and prostate at seven 
Ontario cancer centers between 1982 and 1991 (27). The authors reported 
significant intercentre variations in median waiting times. A third Canadian study 
based on a sample of 1456 cancer patients from eight regional cancer centres in 
Ontario examined several delay intervals, including time from general practitioner 
referral to treatment (32). Patients included in the study were being treated for 
breast, gynecologic, colorectal, head and neck, thoracic, or urologic cancers. 
Median number of days from referral to treatment varied substantially across 
cancer centres (range of a median 19.0 days to 43.0 days). These studies provide 
evidence that equal access and care may not be provided by different centres. 
Although determinants of provider delay have been studied less than those 
of patient delay, some general conclusions can still be drawn. First, the idea that 
younger women experience more provider delay was substantiated by most of the 
studies. This is the opposite of the relationship found for patient delay. It seems 
that providers do not anticipate younger women to have breast cancer because 
they are at lower risk and, as a result, do not treat them as expediently as older 
women who are inherently at greater risk for the disease. Secondly, there is 
moderate evidence that women who present to a physician without a lump wait 
longer. Again, this could be because a lump is recognized as a very common 
46 
indication of breast cancer leading the physicians to act more promptly. Thirdly, 
women who had malignant breast disease were pushed through the system 
quicker than women with benign disease. The last important conclusion that can 
be made is that the region that the patient is treated in (ie., the hospital) or lives in 
(rural versus urban) affects the waiting time. Very few studies examined the 
impact of ethnic origin, administrative problems and previous experience with 
breast disease on provider delay. 
2.6 Summary 
This chapter provided a review of the literature with reference to baseline 
waiting times for breast cancer patients at various intervals in the care pathway, 
the impact that delay has on prognosis and factors associated with patient and 
provider delay. Early studies interviewed patients to determine median waiting 
times, whereas subsequent studies have used cancer registries and databases for 
this purpose. Median waiting times for numerous intervals in the care pathway 
have been reported. Two alarming findings by recent Canadian studies were that 
waiting times have been increasing over time and that an unacceptably small 
fraction of women were treated within the recommended time (29, 30). 
Determining baseline waiting times for intervals in the care pathway leading to 
breast cancer treatment continues to be important for providers assessing the 
appropriateness of waiting times experienced by patients. 
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The impact that delay in the care pathway has on the long-term survival of 
patients is controversial because of the contradictory evidence reported by studies. 
Problems and biases of the studies were discussed in an attempt to explain the 
conflicting results of those studies that reported delay reduced survival and those 
that did not discover this association. There is evidence that long delays by the 
patient and the provider result in worse outcomes. 
Finally, variables that could impact patient and provider delay were 
examined in detail, including age, presenting symptom, socioeconomic status, 
ethnic origin, region and other less studied factors. More studies have focused on 
determining factors associated with patient delay than provider delay. Given the 
evidence that long provider delays can reduce long-term survival, more research 
needs to be done to further substantiate predictors of provider delay. Further 
knowledge of determinants of delay could allow providers to identify patients at 
high risk of experiencing long waits and to design interventions to minimize 
delay. 
The following chapter will briefly describe the rationale for this study 
based on the review of the literature presented in this chapter. It will then outline 
the research questions and the hypotheses for each question. The data source and 
quality will also be discussed. Finally, the variables and statistical methods 
employed to answer the questions will be described. 
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CHAPTER 3: STUDY DESIGN AND METHODOLOGY 
3.1 Introduction 
The previous chapter provided a review of the literature concerning 
baseline waiting times, the impact of delay on survival and factors associated with 
long patient and provider delays. Given that long provider delay was shown to be 
associated with reduced survival and that it has been less studied than patient 
delay, it was noted that more research needs to focus on the provider delay period. 
Coates and associates have indicated that it is important to independently examine 
factors associated with the different subdivisions of provider delay (i.e., from first 
presentation to a general practitioner to specialist referral, first visit with specialist 
to diagnosis, and from diagnosis to initiation of treatment) because different 
interventions to minimize delay could exist for each period (45). Based on these 
findings, this study specifically examined the interval from diagnosis to treatment 
for all women with breast cancer in Alberta in the years of 1997-2000. 
This chapter will outline the research questions and the quantitative 
methods used to answer these questions. It will examine the registry the data 
were obtained from, the study population, the study variables, and the statistical 
methods employed. 
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3.2 Research Questions and Hypotheses 
The objective of this study was to identify predictors of delay between 
diagnosis and treatment for female breast cancer patients in Alberta. Specifically, 
the following questions were addressed: 
1) What are the mean and median waiting times in days between definitive 
diagnosis and treatment for female breast cancer patients in Alberta for each year 
from 1997-2000? 
2) Was there a significant trend in delay over these years? It was hypothesized 
that there was no statistically significant increase in delay between diagnosis and 
treatment each year in the study period. 
3) Do significant waiting time variations between definitive diagnosis and 
treatment exist amongst the 17 defined health regions in Alberta? It was 
hypothesized that there were no statistically significant differences in mean 
waiting times experienced by women from different Regional Health Authorities 
in Alberta. 
4) Do the factors of age, stage, Regional Health Authority, Regional Health 
Authority category, community size at time of diagnosis, and year of diagnosis 
impact the delay interval between diagnosis and treatment experienced by female 
breast cancer patients in Alberta for the years 1997-2000? It was hypothesized 
that all of these factors were not associated with waiting time. 
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3.3 Alberta Cancer Registry 
The Alberta Cancer Registry is a computerized data base of all new 
primary cancer incidents in the province and is operated by the Alberta Cancer 
Board's (ACB) Division of Epidemiology, Prevention and Screening. The 
inclusion of all cancer cases in this registry is mandated by Alberta statutes under 
the Cancer Registry Regulation of the Cancer Programs Act (58). Two centres 
are responsible for the collection of data. The Tom Baker Cancer Institute in 
Calgary is responsible for collecting cancer cases in the southern half of the 
province, while the Cross Cancer Institute in Edmonton maintains data collection 
for the northern half of Alberta (58). 
Quality assurance projects conducted by the ACB have indicated that 95% 
of breast cancer incidents are recorded in the registry (58). Further support for the 
registry's validity and reliability has been the award of the Gold Standard for 
highest degree of data quality by the North American Association of Central 
Cancer Registries, which is a data quality organization (59). The certification is 
based on criteria that are evaluated each year. The criteria for the Gold Standard 
include that the registry be deemed 95% complete, the records are collected 
within 23 months and duplicate records are equal to or less than one in 1000 cases 
in the registry. The high quality of the data enables researchers to conduct valid 
and reliable population-based research. 
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3.4 Study Population 
This population-based study consists of all women diagnosed with breast 
cancer in Alberta for the years of 1997-2000. 
The mean number of Albertans residing in cities during the years of the 
study was 1 817 943, while the average official total population was 2 832 564 
(Table 6) (60). Therefore, on average, approximately 35% of Alberta's 
population lived in rural communities. The large scale of the province and its 
high rural population directly impact the provision of health care. Only two 
tertiary centres within the province provide radiation and chemotherapy treatment 
and specialist follow up care (WW Cross Cancer Institute in Edmonton, RHA 10 
and Tom Baker Cancer Centre in Calgary, RHA 4), five centres offer 
chemotherapy and follow up care (Fort McMurray, RHA 16; Grande Prairie 
Clinic, RHA 13; Lethbridge Clinic, RHA 1; Central Alberta Cancer Centre in Red 
Deer, RHA 6; and Medicine Hat Cancer Clinic; RHA 2), while ten centres 
provide only chemotherapy (Barrhead, RHA 11; Bonnyville, RHA 12; Camrose, 
RHA 7; Drumheller, RHA 5; High River, RHA 3; Hinton, RHA 8; Peace River, 
RHA 14; Lloydminster, RHA 7; and Bow Valley, RHA 3) (Table 7, Figure 3) 
(61). 
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Table 6: A summary of the Alberta population for the years of 1997-2000. 
Population 1997 1998 1999 2000 
City* 1 757 246 1 783113 1 851 449 1 879 962 
Official Total 2 744 731 2 781 290 2 871 271 2 932 963 
Female 1 407 411 1 440 171 1 465 495 1 490 571 
*Cities include: Airdrie, Calgary, Camrose, Drumheller, Edmonton, Fort 
Saskatchewan, Grande Prairie, Leduc, Lethbridge, 
Medicine Hat, Red Deer, Spruce Grove, St. Albert, and 
Wetaskiwin (60). 
Table 7: A summary of where in Alberta various cancer services are provided. 
Type of Treatment 
Provided 
Locations in Alberta 
Radiation, chemotherapy, 
and specialist follow up 
WW Cross Cancer Institute, Edmonton (RHA 10) 
Tom Baker Cancer Centre, Calgary (RHA 4) 
Chemotherapy and specialist 
follow up 
Fort McMurray (RHA 16) 
Grande Prairie Cancer Clinic (RHA 13) 
Lethbridge Cancer Clinic (RHA 1) 
Central Alberta Cancer Centre, Red Deer (RHA 6) 
Medicine Hat Cancer Clinic (RHA 2) 
Chemotherapy Barrhead (RHA11) Bonnyville (RHA 12) 
Bow Valley (RHA 3) Camrose (RHA 7) 
Drumheller (RHA 5) High River (RHA 3) 
Hinton (RHA 8) Lloydminster (RHA 7) 
Peace River (RHA 14) 
53 
3.5 Study Variables 
After ethics approval was obtained, individual breast cancer data for the 
years of 1997-2000 were obtained from the Alberta Cancer Board. The variables 
obtained include: age of patient, stage of disease, date of diagnosis, date of 
treatment, postal code at time of diagnosis, and Regional Health Authority 
(RHA). The variables of interest in this study are age, stage, RHA, RHA 
category, community size of residence, year of diagnosis, and time between 
definitive diagnosis and treatment. Some of these variables were used directly 
from the obtained data (ie. age, stage and RHA), while others were computed and 
coded by the researcher using the given information (ie. RHA category, 
community size, and time between diagnosis and treatment). These variables 
were defined and coded as follows: 
A) Age: is defined in the registry and this study as the number of years 
old the patient was at diagnosis. 
B) Stage: is coded by the registry as 1, 2, 3, or 4 with each stage being 
considered more severe than the last. The stage is the result of an 
algorithm that searches the patient's chart for any pathological and clinical 
stage information. An aggregate stage (stage 1-4) is based on information 
regarding tumor size, involvement of lymph nodes and whether or not the 
cancer has metastasized (TNM components- tumor node metastasis). 
Stage 1 cancers involve tumors less than 2cm that have not spread; Stage 2 
cancers are defined as tumors 2cm-5cm with or without spread to lymph 
nodes; Stage 3 cancers involve tumors >5cm with or without spread to 
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lymph nodes; and all cancers that have spread to other parts of the body 
are classified as Stage 4, regardless of size and lymph node involvement 
(62). If an aggregate stage (1-4) is found in the chart, it is used; however, 
if no aggregate stage is indicated, the algorithm is used to obtain stage 
from TNM components of stage indicated in the chart. If no staging 
information is found in the chart, no stage is indicated in the registry. 
C) RHA: is the health region the patient lived in at the time of her 
diagnosis. During the period studied, Alberta was divided into 17 health 
regions. These 17 RHAs were responsible for the hospitals and 
community and public health services within their designated borders. 
The population and resources of the health regions varied considerably. 
The registry used the 2001 boundaries to define RHA regardless of year(s) 
of data requested (Figure 2). No border changes during the period studied 
were identified. 
D) RHA Category: is an unofficial categorization of RHAs into those 
considered to be "urban", "rurban" and "rural". The category an RHA 
belongs to is based on the cancer services it can provide. An urban RHA 
is one that offers tertiary cancer treatment (radiation, chemotherapy and 
specialist follow up), a rurban RHA can provide secondary cancer 
treatment (chemotherapy and specialist follow up) and usually has a 
midsize community with surrounding rural communities within its 
boundaries, and a rural RHA has no secondary or tertiary treatment centre 
(Table 7). Of the 17 RHAs in Alberta, two were considered urban (#4 
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Calgary Health Region and #10 Capital Health Authority), five were 
considered rurban (#1 Chinook Health Region, #2 Palliser Health 
Authority, #6 David Thompson Regional Health Authority, #13 Mistahia 
Regional Health Authority, and #16 Northern Lights Regional Health 
Authority) and the other 10 were considered rural (Figure 2). 
E) Community Size: was categorized as residences consisting of more 
than 100 000 people, 10 000-100 000 people, and less than 10 000 people. 
The patient's postal code at time of diagnosis was converted to the specific 
residence using a Postal Code Converter Instrument obtained from Alberta 
Health and Wellness. In Alberta, only two communities have more than 
100 000 residents and 17 have between 10 000 and 100 000 residents 
(Table 8). 
F) Year of Diagnosis: was considered as 1997, 1998, 1999, or 2000. 
G) Time between Diagnosis and Treatment: was calculated as the 
continuous number of days between the given dates for diagnosis and 
treatment. If the patient had more than one diagnostic test, the date of 
diagnosis recorded in the registry was the date of the last diagnostic test, 
which is considered to be the definitive diagnosis. The date of treatment 
was considered as the first day treatment was obtained. In almost all 
cases, the definitive treatment would be surgical intervention (either a 
mastectomy or a lumpectomy). 
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Age, stage, RHA, RHA category, population of residence, and year of 
diagnosis are the independent variables and the number of days between diagnosis 
and treatment is the dependent variable in this study. 
Table 8: Cities included in the three population categories. 
Population Alberta Cities Included 
Category 
>100 000 residents Calgary 
Edmonton 
10 000-100 000 Airdrie Brooks 
residents Camrose Canmore 
Cochrane Cold Lake 
Drumheller Fort Saskatchewan 
Grande Prairie Leduc 
Lethbridge 
Medicine Hat 
Lloydminster 
Red Deer 
Spruce Grove St. Albert 
Wetaskiwin 
<10 000 residents All other communities not mentioned 
above 
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3.6 Statistical Methods 
The data were analyzed using various statistical functions contained in the 
Statistical Package for the Social Sciences (SPSS) 11.0. 
Prior to the analyses all variables were reviewed for accuracy of data 
entry, missing values, univariate and multivariate outliers, and fit between their 
distributions and the assumptions of multivariate analysis (including normality, 
linearity, homoscedasticity, and non-multicollinearity). Missing data determined 
to be random and less than 3% of the total sample were excluded, whereas non-
random missing data were imputed using the missing data regression option of 
Linear Trend at Point in SPSS. Frequency distributions and Mahalanobis distance 
(distance of a case from the centroid of the remaining cases where the centroid is 
the point created by the means of all the variables) with p<0.001 were utilized to 
assess the presence of univariate and multivariate outliers, respectively (63). 
Histograms and values of skewness and kurtosis were used to determine 
normality of each variable's distribution. Data with moderate skewness (<2) or 
kurtosis (<5) were transformed using square root transformations. Data with 
excessive skewness (2-5) or kurtosis (>5) were altered using a log transformation. 
The assumptions of linearity and homoscedasticity were revealed by bivariate 
scatterplots of each pair of variables. Variables that did not portray a linear 
relationship with length of waiting time (RHA, age, stage) were recoded or 
collapsed into new categories that did indicate the assumed linear trend. RHA 
was dummy coded into a set of dichotomous variables. For example, cases were 
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considered either from RHA 1 or not, RHA 2 or not, RHA 3 or not and so on. 
Multicollinearity was identified using SPSS collinearity diagnostics. The criteria 
used to identify multicollinearity were a conditioning index of greater than 30 and 
two variance proportions greater than 0.5, as suggested by Tabachnik and Fidell 
(63). 
Descriptive statistics were used to illustrate waiting times from diagnosis 
to treatment for the population over the entire period of the study, for each year, 
and for various subgroups of each independent variable. The means and medians 
were both reported, but the medians were used more for graphing because this 
measure of central tendency is less subject to bias from extreme cases. To 
determine if significant differences in the waiting times for women in different 
subgroups of each variable (age, stage, community size, RHA group, year of 
study and RHA) existed, the nonpar ametric Kruskal Wall is test was used. If the 
test indicated that there was a significant difference, Dunn post hoc tests were 
used to specify the groups that had significant variations in waiting time. For the 
"stage missing" versus "stage not missing variable", a Mann-Whitney U test was 
used because there were only two independent samples to compare. 
Nonparametric tests were used instead of the parametric analysis of variance 
(ANOVA) or independent t-tests because of unequal sample sizes in each 
category being compared. 
Finally, standard multiple linear regression was used to examine the 
correlates of waiting time between diagnosis and treatment for breast cancer 
patients using the following variables as predictors: age, stage, RHA, community 
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size, and year of diagnosis. A decision was made not to include RHA category as 
a predictor variable because of likely high multicollinearity with RHA. Standard 
regression was chosen because there was no theoretical basis for choosing either 
sequential or stepwise variable entry. To ensure that important variables are 
entered into and not excluded from the model, the default probability of F at entry-
was altered from 0.05 to 0.10 and the exit value changed from 0.10 to 0.15, which 
was also suggested by Tabachnik and Fidell (63). Two separate regressions were 
run using different methods for dealing with the missing data to determine if the 
missing data was a good predictor itself. First, a new and predictor variable was 
created for "missing stage" versus "stage not missing" and the missing values in 
the original stage variable were imputed using SPSS Linear Trend at Point. 
Secondly, the analysis was repeated using only complete cases. 
After examining the results from the univariate and multivariate analyses, 
it was decided to repeat the regression using a dichotomized south or north RHA 
variable instead of dummy coded RHA variables. RHAs 1-6 were considered 
southern, while RHAs 7-17 were considered northern. An independent t-test was 
also used to test for significant differences between mean waiting times of 
southern and northern RHA patients. A parametric test was chosen because both 
groups had a similar number of women. 
3.7 Summary 
This chapter provided brief justification for this study based on the 
findings from the literature presented in the previous chapter. It was noted that 
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there is a lack of studies examining system delay and that components of system 
delay should be independently assessed. 
This chapter also presented the objective and specific research questions 
of the study. This study will determine baseline waiting time data for Alberta 
breast cancer patients and examine the effect that age, stage, RHA, RHA 
category, population, and year of diagnosis have on length of waiting time 
between diagnosis and treatment in Alberta. 
The data source (ie. the Alberta Cancer Registry) was described in terms 
of who collects the data, the reliability of it and the variables it contains. 
Although relatively few variables are available, the strength of the data is that is it 
very reliable and represents the population of breast cancer patients in Alberta. 
Finally, this chapter described the statistical methods that were employed 
to answer the research questions. Descriptive, nonparametric and multivariate 
procedures were used. Standard multiple regression was used to build a predictor 
model of delay and indicate the relative importance of variables for the prediction 
of waiting time. 
The following chapter will present the results from the analyses. It will 
statistically describe the population; waiting time data for the population and 
various subgroups; the groups that have significantly different waiting times; and 
the regression model. 
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CHAPTER 4: RESULTS 
4.1 Overview 
The previous chapter outlined the research questions, defined the study 
variables and discussed the statistical methods employed. The purpose of this 
chapter is to present the results from the analysis. It will describe the study 
sample and the data screening and cleaning conducted prior to analysis. Finally, 
it will illustrate the univariate and multivariate test results. 
4.2 Sample 
Over the 4-year study period, there were a total of 6418 female breast 
cancer cases recorded in the Alberta Cancer Registry. There were 1578 cases 
(24.6%) in 1997, 1482 cases (23.1%) in 1998, 1687 cases (26.3%) in 1999, and 
1671 (26%) cases in 2000. 
A description of characteristics of the study population is presented in 
Table 9. The mean age of the breast cancer patients was 60.5 (SD=14.4) ranging 
from 10 to 99 years of age. Those cases under the age of 20 were later removed 
(see section 4.3). The 51-60 years age group represented the largest percent of the 
population (23.2%). Fewer than 10% of the patients had stage 3 or 4 disease and 
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Table 9: A summary of the characteristics of the study population. 
Variable Total no. 1997 1998 1999 2000 
(and %) (%) (%) (%) (%) 
Age Group 
<30 37 (0.6) 0.5 0.5 0.5 0.7 
31-40 473 (7.4) 7.2 8.0 7.7 6.6 
41-50 1329 (20.7) 20.8 21.4 19.5 21.2 
51-60 1486 (23.2) 23.4 21.0 23.8 24.2 
61-70 1301 (20.3) 19.2 21.1 21.6 19.2 
71-80 1184 (18.4) 19.5 18.3 17.9 18.2 
81-90 541 (8.4) 8.3 8.6 8.3 8.6 
>90 67 (1.0) 1.1 1.1 0.8 1.3 
Stage 
1 2348 (36.6) 34.5 36.8 36.2 38.7 
2 2169 (33.8) 31.8 33.9 35.1 34.3 
3 386 (6) 6.5 6.2 5.8 5.6 
4 207 (3.2) 3.7 3.4 3.0 2.8 
unknown 1308 (20.4) 23.4 19.7 19.8 18.7 
RHA Category 
1 345 (5.4) 5.5 5.6 5.2 5.3 
2 187 (2.9) 3.0 3.0 2.7 2.9 
3 165 (2.6) 2.9 3.2 2.4 1.9 
4 1981 (30.8) 30.0 29.1 31.9 32.1 
5 147 (2.3) 2.2 2.6 2.0 2.5 
6 405 (6.3) 6.7 5.4 6.2 6.9 
7 253 (4) 4.1 3.8 3.6 4.2 
8 177 (2.7) 3.0 3.4 2.5 2.3 
9 66 (1) 0.9 0.9 1.3 1.0 
10 1973 (30.8) 29.8 31.5 31.6 30.1 
11 204 (3.2) 3.6 3.0 3.6 2.5 
12 191 (3) 3.5 2.6 2.4 3.5 
13 175 (2.7) 2.1 3.6 2.5 2.8 
14 52 (0.8) 0.8 0.7 0.8 0.9 
15 33 (0.5) 0.7 0.8 0.2 0.4 
16 48 (0.8) 1.0 0.6 0.9 0.4 
17 16 (0.2) 0.3 0.1 0.3 0.4 
RHA Category 
Rural 1302 (20.3) 21.9 21.1 18.9 19.4 
Rurban 1162 (18.1) 18.3 18.3 17.6 18.3 
Urban 3954 (61.6) 59.8 60.6 63.6 62.3 
Community Size 
<10 000 2582 (40.2) 41.9 41.2 38.2 39.9 
10 000- 100 000 625 (9.8) 9.5 9.5 9.3 10.7 
>100 000 3211 (50.0) 48.6 49.3 52.5 49.4 
there was a small decrease in the percent of these more severe cases over the 
period of the study. Overall, nearly 19% of cases did not have a recorded stage. 
Fifty percent of the women lived in an urban RHA at time of diagnosis. Only 
9.8% of cases were from an area of residence with a population between 10 000-
100 000, while 40.2% were from an area with <10 000 people. 
4.3 Data Screening and Analysis of Multivariate Assumptions 
Prior to analysis, all variables were reviewed for accuracy of data entry, 
identification of missing values and outliers, and the fit between their distributions 
and the assumptions of multivariate analysis, including normality, linearity, 
homoscedasticity, and non-multicollinearity. 
Of the 6418 cases, 180 cases (<3% of total data) did not have a recorded 
waiting time. The waiting time for these cases was missing either because it was 
not recorded in the data base or because the date of treatment was recorded as 
occurring before the date of diagnosis. The 180 missing values were deemed to 
be random and constituted a very small portion of the population and, thus, were 
deleted from further analyses. After deletion of these cases, it was established 
that 1169 cases (19% of total data) had a missing stage variable. An independent 
r-test indicated that those with a stage were significantly older than those with no 
recorded stage (t=19.9, p<0.001); therefore, the missing data were not random. 
Because of the possibility that missing stage values could be good predictors of 
waiting time, two separate regressions were run using different methods for 
dealing with the missing data. First, a new variable was created for missing stage 
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versus stage not missing and the missing values in the original stage variable were 
imputed using SPSS Linear Trend at Point. Secondly, the analysis was repeated 
using only complete cases. No other variables presented missing data. 
Univariate and multivariate outliers were determined through examination 
of each variable's distribution and the Mahalanobis distances for each case with 
p<0.001, respectively. The frequency distribution of age showed two outlying 
cases under the age of 20. Both of these cases were deleted from the analysis due 
to suspicion that they were originally entered into the data base incorrectly. No 
other outliers were identified. 
The individual variables were screened for normality through histograms 
and values of skewness and kurtosis. Waiting time was severely skewed due to 
the large number of women who received treatment the same day as their 
diagnosis. A logarithmic transformation normalized this variable. The moderate 
skewness of stage was corrected with a square root transformation. The other 
variables demonstrated histograms and values of skewness and kurtosis that 
approximated the normal distribution. 
The assumptions of linearity and homoscedasticity were revealed by 
bivariate scatterplots of each pair of variables. Age group, and stage portrayed a 
non-linear relationship with log waiting time. Subsequently, these variables were 
recoded into groups that did demonstrate a linear trend. Stage was dichotomized 
into those cases diagnosed with Stage 1 disease versus those with Stage 2, 3 or 4. 
Similarly, age was collapsed into those patients 70 years and younger, 71-80, 81-
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90, and older than 90 years. RHA was dummy coded into a set of dichotomous 
variables. For example, women were considered to be either from RHA 1 or not. 
Screening for multicollinearity and singularity was accomplished using 
SPSS collinearity diagnostics in which conditioning indexes and variance 
proportions are produced for each variable. No variables had an index greater 
than 30 or a variance proportion greater than 0.5, which Tabachnik and Fidell 
define as criteria of multicollinearity (63). 
4.4 Descriptive Statistics and Univariate Analyses 
Tables 10-13 and Figures 4-11 present variations in time from definitive 
diagnosis to definitive treatment for various subgroups of the six independent 
variables. The overall mean waiting time was 20.2 days (SD = 21.6), while the 
median was 17 days. The waiting time ranged from 0 days to 243 days (Table 10). 
Nearly 27% of women (1709) began treatment the same day as their diagnosis (0 
days). Only 43.8% of the population was treated within the recommended 14 
days established by the Canadian Society for Surgical Oncology (CSSO). Ninety 
percent of women were treated within 43 days of their diagnosis. 
For purposes of reporting, age was categorized into those cases: <31, 31-
40, 41-50, 51-60, 61-70, 71-80, 81-90, or >90. There is variation in the mean and 
median waiting times of women in different age groups, which is illustrated in 
Table 10 and Figure 5. The median waiting times for the 51-60 and 61-70 age 
groups were both 19 days (means of 21.5 and 20.8 days, respectively), while the 
>90 age group experienced a median delay of 0 days (mean of 18.6 days). A 
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Kruskal Wallis test indicated significant differences in the medians of waiting 
times of women in different age groups (H=87.954, p<0.001). Dunn post hoc 
tests determined that those younger than 70 waited, on average, significantly 
longer than each of the older age groups (p<0.05). Similarly, women who were 
71-80 years old waited, on average, appreciably longer than the two older age 
groups. A separate analysis of those cases with zero days between diagnosis and 
treatment was conducted to establish if there was an association with age. Table 
11 demonstrates that from the 41-50 year age group through to the oldest group, 
there was a steady increase in the percent of women who did not wait to receive 
treatment. 
Table 10 and Figure 6 present the waiting time distribution by stage of 
disease and reveal that women with stage 1 wait the longest for treatment. 
Women with stage 1, 2, 3, and 4 disease experienced a median (and mean) delay 
of 20 days (22.1 days), 15 days (17.5 days), 14 days (18.2 days), and 14 days 
(18.5), respectively. Cases with no recorded stage waited a median of 18 days 
and a mean of 22.4 days. The Kruskal Wallis test indicated that there was a 
significant difference in the median waiting times of women diagnosed with 
different stages of breast cancer (H= 82.140, p<0.001). Dunn post hoc 
comparisons specified that women with no recorded stage or with stage 1 disease 
waited, on average, significantly longer than all other stages (p<0.05). No other 
stages demonstrated significant waiting time differences. The Mann-Whitney U 
test indicated that there was no significant difference in waiting times for women 
with and without a recorded stage (U=2883254, p=0.138). 
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There was little variation in the mean and median waiting times of women 
from different community sizes, as portrayed in Table 10 and Figure 7. Women 
from communities with less than 10 000 residents waited a median of 18 days and 
a mean of 20.4 days. The two larger community sizes of 10 000-100 000 and 
>100 000 residents presented median waiting times of 17 days and respective 
mean waiting times of 19.5 and 20.1 days. The Kruskal Wallis test indicated that 
there was no significant difference in the median waiting times of women from 
different community sizes (H= 1.791, p=0.408). 
Table 10 and Figure 8 describe the waiting time distribution by RHA 
group and illustrate variation in waiting times associated with the different 
groups. Women living in an urban, rurban or rural RHA experienced a median 
(and mean) delay of 17 days (20.5 days), 14 days (18.0 days), and 19 days (21.5 
days), respectively. The Kruskal Wallis test indicated that there was a significant 
difference in the median waiting times of women from different RHA categories 
(H= 30.439, p<0.001). Dunn post hoc comparisons specified that women who 
lived in rurban RHAs waited, on average, significantly less than women in rural 
or urban RHAs (p<0.05). 
There was a yearly trend of increased mean and median waiting times, 
which is demonstrated in Table 10 and Figures 9 and 10. The median and mean 
waiting times increased by an average of two days each year of the study. The 
Kruskal Wallis test indicated that there was a significant difference in the median 
waiting times of women diagnosed in different years (H=86.199, p<0.001). Dunn 
post hoc tests specified that women diagnosed in 1997 waited, on average, 
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significantly less than women diagnosed in 1999 or 2000 and women diagnosed 
in 1998 or 1999 waited significantly less than women diagnosed in subsequent 
years (p<0.05). Furthermore, the percentage of women waiting more than two 
weeks for treatment increased each year from 49.7% in 1997 to 63.9% in 2000 
(Figure 9). 
Waiting times also varied in different RHAs (Tables 12 and 13 and Figure 
11). The median and mean waiting times ranged from 11 days to 22.5 days and 
from 15.4 days to 28.6 days, respectively. The Kruskal Wallis test indicated that 
there was a significant difference in the median of waiting times of women from 
different RHAs at diagnosis (H= 160.056, p<0.001). Dunn post hoc tests 
specified that women living in RHA 1 experienced significantly less delay than 
those from RHAs 7, 9, 10, 11, 12, and 13, women from RHA 2 less than those 
from RHAs 10 and 12, women from RHA 4 less than those from RHAs 10, 12, 
and 13, and women from RHA 6 less than those from RHAs 9, 10, 12, and 13. 
An independent t-test indicated that women from southern RHAs waited, on 
average, significantly less than women from northern RHAs (t= 9.101, p<0.001) 
(Table 10, Figure 12). Box plots showing the 95% confidence intervals of the log 
waiting times for each RHA also portrays that Southern RHAs are generally lower 
than the population mean waiting time, while the Northern RHAs are generally 
higher (Figure 13). 
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Table 10: Waiting time from diagnosis to treatment initiation for breast cancer 
patients in Alberta for the years of 1997-2000. 
Characteristic No. of Median Mean 90 t h % women 
Episodes Wait Wait percentile waiting 
(n) Time (d) Time (d) wait 
time (d) 
>14 days 
Age group (yr) 
<31 34 16 22.3 48 54.5 
31-40 468 15 18.4 38 50.2 
41-50 1306 17 20.9 44 58.5 
51-60 1460 19 21.5 43 62.1 
61-70 1273 19 20.8 44 59.0 
71-80 1143 16 19.2 43 52.7 
81-90 502 6 17.6 46 41.7 
>90 52 0 18.6 45 34.6 
Stage 
Unknown 1169 18 22.4 51 56.7 
1 2333 20 22.1 44 62.6 
2 2158 15 17.5 40 50.8 
3 377 14 18.2 42 49.9 
4 201 14 18.5 36 47.5 
Population 
<10 000 2510 18 20.4 43 56.9 
10 000-100 000 609 17 19.5 43 55.2 
>100 000 3119 17 20.1 44 55.8 
RHA Group 
Urban 3848 17 20.5 44 57.4 
Rurban 1125 14 18.0 42 48.6 
Rural 1265 19 21.5 44 59.4 
Year of Study 
1997 1521 14 17.9 40 49.7 
1998 1447 16 18.2 39 51.8 
1999 1651 18 20.9 44 58.3 
2000 1619 20 23.6 50 63.9 
RHA Position 
South 3144 14 17.8 41 48.4 
North 3094 20 22.7 46 64.1 
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Table 11: A description of the number and percentage of women, by age group, 
waiting zero days for breast cancer surgery in Alberta between 1997 and 2000. 
Age Category Number of Women % of Women 
Waiting 0 days Waiting 0 days 
<31 6 18.2% 
31-40 115 24.6% 
41-50 274 21.0% 
51-60 315 21.6% 
61-70 342 26.9% 
71-80 386 33.8% 
81-90 241 48.1% 
>90 30 57.7% 
Table 12: Waiting time from diagnosis to treatment for breast cancer in each RHA 
in Alberta between the years of 1997 and 2000. 
RHA No. of Median Mean 90 t h % women 
Episodes Wait Wait percentile waiting 
(n) Time (d) Time (d) wait 
time (d) 
>14 days 
1 338 13 15.4 34 43.8 
2 182 11 20.2 47 48.7 
3 161 14 18.1 43 46.6 
4 1928 14 18.1 43 49.3 
5 144 17 19.4 45 54.9 
6 390 12.5 16.1 39 45.6 
7 245 20 22.7 47 60.8 
8 172 17.5 18.9 37 58.7 
9 66 22.5 22.4 47 65.2 
10 1919 20 22.8 46 65.5 
11 201 19 23.3 50 60.7 
12 182 21.5 22.5 44 68.7 
13 167 21 24.8 55 63.5 
14 50 17 25.1 61 60.0 
15 31 21 28.6 49 58.1 
16 46 15 18.3 30 54.3 
17 15 13 23.4 73 40.0 
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Table 13: Waiting time from diagnosis to treatment for breast cancer in 
each RHA in Alberta for each year from 1997-2000. 
RHA Wait times 
n, median (d) 
1997 
Wait times 
n, median (d) 
1998 
Wait times 
n, median (d) 
1999 
Wait times 
n, median (d) 
2000 
1 85 (9) 80 (11.5) 87 (14) 86 (14) 
2 47 (0) 44 (5.5) 44 (10.5) 47 (23) 
3 45 (19) 45 (8) 40 (10.5) 31 (20) 
4 455 (13) 424 (14) 529 (13) 520 (19) 
5 33 (11) 38 (14) 33 (17) 39 (21) 
6 97 (2) 79 (14) 102 (12.5) 112 (15.5) 
7 65 (17) 55 (21) 60 (18.5) 65 (23) 
8 46 (19.5) 50 (15.5) 39 (19) 37 (17) 
9 14 (24.5) 14 (7.5) 22 (18) 16 (24) 
10 452 (16) 454 (17) 521 (21) 492 (21) 
11 57 (19) 45 (14) 58 (19.5) 41 (26) 
12 52 (20) 36 (21) 39 (22) 55 (22) 
13 31 (9) 49 (18) 40 (27.5) 47 (21) 
14 12 (14) 11 (13) 12 (28.5) 15 (20) 
15 10 (26.5) 12 (24) 3 (15) 6 (16) 
16 15 (16) 9 (14) 16 (18.5) 6 (22) 
17 4 (1) 2 (13) 5 (3) 4 (60) 
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4.5 Multivariate Analysis 
Multivariate modeling using linear regression in SPSS was used to 
produce estimates of the independent effect of age, stage, stage missing, RHA, 
community size, and year of diagnosis in a predictor model for the system delay 
interval of diagnosis to treatment. The predictor variables were entered 
simultaneously. 
The regression that computed a new variable of stage missing versus 
present resulted in a slightly larger value of variance accounted for; therefore, 
only the results from the regression that imputed the missing stage values is 
presented. Table 14 displays the correlations between the variables. Table 15 
displays the unstandardized regression coefficients (B), the standardized 
regression coefficients (p), the semi-partial correlations (sr^), the amount of 
variation in waiting time accounted for by the predictor variables (R 2), and 
adjusted R 2 . R for regression was significantly different from zero (F = 29.396, 
p<0.001). Four of the five non-dummy coded variables contributed significantly 
to the prediction of wait time as logarithmically transformed: age (srj2= 0.026), 
stage (sr;2= 0.014), stage missing versus stage recorded (sn 2= 0.010 ), and year of 
diagnosis (sr;2= 0.012). Eleven of the RHA dummy coded variables also 
significantly contributed to the prediction of log waiting time: RHA 6 (sr; = 
0.002), RHA 7 (srj2= 0.004), RHA 8 (srf= 0.002), RHA 9 (srf= 0.001), RHA 10 
(sn 2= 0.024), RHA 11 (srf= 0.005), RHA 12 (srf= 0.006), RHA 13 (srj2= 0.003), 
RHA 14 (sr 4 2= 0.001), RHA 15 (srf= 0.001), and RHA 16 (srf= 0.001). 
Altogether, 9% (8.7% adjusted) of the variability in waiting time from diagnosis 
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to treatment for Alberta breast cancer patients was predicted by knowing the 
scores on all six predictor variables. 
Because the significant waiting time variations appeared to be between 
Southern and Northern RHAs, a second regression using a dichotomized South 
(RHAs 1-6) or North (RHAs 7-17) RHA variable was performed. There was no 
increase in the amount of variation accounted for (R 2= 0.087). 
Table 14: The correlation values for all pairs of variables entered into the linear 
regression analysis. 
Variables Age RHA Stage Stage 
Missing 
Community 
Size 
Year of 
Diagnosis 
Time -.145** -.110** .004 .013 .102** 
Age .086** -.264** .008 .008 
RHA 
Stage -.371** -.001 -.026* 
Stage 
Missing 
-.029* .036** 
Community 
Size 
-.023 
Year of 
Diagnosis 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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Table 15: Standard multiple regression using RHAs, age, stage, stage missing or 
recorded, community size and year of diagnosis as predictor variables of log 
waiting time from diagnosis to treatment for breast cancer patients. 
Variable Regression Standardized Squared 
Coefficients Regression Semi-Partial 
(B) Coefficients Correlations 
(P) (sri 2) 
RHA 1 dummy -0.005 -0.002 0.000 
RHA 2 dummy -0.019 -0.005 0.000 
RHA 3 dummy 0.075 0.018 0.000 
RHA 5 dummy 0.039 0.009 0.000 
RHA 6 dummy -0.113** -0.042 0.002 
RHA 7 dummy 0.232** 0.069 0.004 
RHA 8 dummy 0.196** 0.049 0.002 
RHA 9 dummy 0.185* 0.029 0.001 
RHA 10 dummy 0.260** 0.184 0.024 
RHA 11 dummy 0.274** 0.074 0.005 
RHA 12 dummy 0.320** 0.083 0.006 
RHA 13 dummy 0.227** 0.056 0.003 
RHA 14 dummy 0.189* 0.026 0.001 
RHA 15 dummy 0.280* 0.030 0.001 
RHA 16 dummy 0.211* 0.028 0.001 
RHA 17 dummy 0.029 0.002 0.000 
Age -0.165** -0.169 0.026 
Stage -0.169** -0.126 0.014 
Stage missing/ -0.187** -0.112 0.010 
present 
Community Size -0.0006 -0.006 0.000 
Year of diagnosis 0.006** 0.107 0.012 
R 2 = 0.090**, adjusted R 2 = 0.087. 
** p<0.01, * p<0.05 
Note: RHA was dummy coded into a set of dichotomous variables and age and 
stage were receded to provide variables that demonstrated linear relationships 
with waiting time. Age was collapsed into patients <70 and all other older groups 
remained the same. Stage was transformed into cases with stage 1 cancer versus 
those with stage 2, 3, 4 or missing (which was imputed using SPSS Linear Trend 
of Point). 
86 
4.6 Summary 
The median waiting time from diagnosis of breast cancer to treatment in 
Alberta was 17 days for the period 1997 to 2000. The mean and median waiting 
times increased each year of the study by an average of two days. Furthermore, 
the majority of women were not treated within the recommended 14 days after 
diagnosis. Each year, the percentage of patients not treated within this 
recommended time increased by an average of 4.7%. 
Very little (9%) of the variation in the waiting time between diagnosis and 
breast cancer treatment was explained by the developed model. The relative 
importance of predictors of delay was found to be: living in RHA 10 at diagnosis, 
age at diagnosis, stage of breast cancer, stage missing or recorded, year of 
diagnosis, followed by several other significant RHAs. 
Univariate and multivariate analyses indicated that there was significant 
variation in waiting times for women from different RHAs at time of diagnosis. 
Further examination portrayed that women from southern RHAs (1-6) waited, on 
average, significantly less than women from northern RHAs (7-17). Univariate 
analysis indicated that women from rurban RHAs experienced less delay than 
women from rural and urban RHAs, but no significant difference was found 
between rural and urban patients. 
Women who were less than 70 years old at diagnosis waited significantly 
longer to be treated than women who were older. Older age was also associated 
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with an increased likelihood of receiving a diagnosis of breast cancer and 
treatment on the same day. 
Patients diagnosed with Stage 1 disease waited significantly longer for 
treatment than women with Stage 2, 3 or 4 disease. Univariate and multivariate 
analyses confirmed that no difference in the waiting times for women with Stage 
2, 3, or 4 existed. Multivariate regression indicated that women with no recorded 
stage waited significantly longer than women with a staged disease. 
The following chapter will discuss these findings. It will provide specific 
answers to the research questions presented in Chapter 3. I will present possible 
explanations for the results pertaining to each variable and compare the findings 
of this study to similar studies encountered in the literature review. Finally, it will 
recognize the limitations and strengths of the study and make recommendations 
for future research. 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
5.1 Introduction 
The previous chapter presented the results from the statistical analysis. 
The purpose of this chapter is to discuss the findings of this study. It will provide 
answers to the research questions outlined in Chapter 3, discuss the findings with 
respect to each variable and compare the results to those identified in the literature 
review. Furthermore, it will recognize the limitations and strengths of the study 
and present ideas for future research. 
5.2 Research Questions Answered 
Ql: What are the mean and median waiting times in days between definitive 
diagnosis and treatment for female breast cancer patients in Alberta for each year 
from 1997-2000? 
Al . The overall mean and median waiting times for breast cancer surgery in 
Alberta was 20.2 days and 17 days, respectively. In 1997 the mean was 17.9 days 
and the median was 14 days; in 1998 the mean was 18.2 days and the median was 
16 days; in 1999 the mean was 20.9 days and the median was 18 days; and in 
2000 the mean was 23.6 days and the median was 20 days. 
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Q2: Was there a significant trend in delay over these years? 
A2: Dunn post hoc tests specified that there was a significant increase in the 
mean waiting time each year from 1998-2000 (H=86.199, P<0.001). 
Q3: Do significant waiting time variations between definitive diagnosis and 
treatment exist amongst the 17 defined health regions in Alberta? 
A3: Significant variations in waiting times for women from different RHAs at 
diagnosis were indicated by Dunn post hoc tests. Women from Southern RHAs 
(1-6) experienced, on average, significantly less delay than women from Northern 
RHAs (7-17). Furthermore, women who were residents of rurban RHAs waited, 
on average, significantly less than women from urban and rural RHAs. 
Q4: Do the factors of age, stage, regional health authority, regional health 
authority category, community size at time of diagnosis, and year of diagnosis 
impact the delay interval between diagnosis and treatment experienced by female 
breast cancer patients in Alberta for the years 1997-2000? 
A4: Age, stage, RHA, and year of diagnosis were significant predictors of 
waiting time in multivariate analysis. RHA category, which was not included in 
the multivariate model, was significantly associated with waiting time in the 
univariate analysis. 
5.3 Discussion of Findings 
Given the evidence that long delays can negatively impact the survival of 
breast cancer patients, one major purpose of this study was to determine waiting 
time from diagnosis to treatment and compare the length to other literature reports 
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and recommended guidelines. There are methodological obstacles to a direct 
comparison between the median wait time result in this study with other studies 
because of the numerous definitions of delay intervals and differences in the 
health care systems. The median of 17 days between diagnosis and treatment in 
Alberta established by this study is higher than the 10 days reported by an 
American study (28) and lower than two Canadian studies that reported 20 days 
between treatment decision and treatment in Ontario (32) and 24 days between 
diagnostic procedure to treatment in Quebec (29). The differences in the 
American and Canadian health care systems could account for the first 
discrepancy. The nature of American health service delivery leads to more 
capacity and the ability of insured patients to be treated quickly. Whereas in 
Canada, capacity is often maximally utilized and wait lists are common. Further 
examination and comparison of care pathway structure in Alberta, Quebec, and 
Ontario would have to be conducted before rationalizing the differences in the 
waiting times of these provinces. 
The proportion of patients receiving treatment within the Canadian 
Society for Surgical Oncology (CSSO) recommended 14 days after diagnosis was 
43.8% (33). Although this is higher than the 32.5% of cancer patients meeting the 
guideline reported in Ontario by Simunovic et al (32), it is unacceptable that the 
majority of women are not treated within the time set by an expert group. The 
recommendation of 14 days may not be sufficiently emphasized or practiced by 
physicians as it may seem unattainable. It is important to note that this is a 
recommended guideline not based on evidence that treating patients within two 
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weeks improves survival. Studies need to be conducted to elucidate the optimal 
time in which breast cancer patients should be treated. 
The second major purpose of this study was to determine factors that 
predicted variation in waiting times. The regression model developed using 
characteristics of the patient (including age, stage of disease, stage recorded or 
missing, RHA, community size, and year of diagnosis) explained 9% of the 
variation in waiting times. Even though the variation accounted for was small, six 
of the seven variables were significant predictors of delay and potentially 
modifiable. 
Age at diagnosis was the variable most consistently associated with 
system delay in the literature and in this study. Of the nine studies that examined 
the impact of age on provider delay, two reported no significant relationship 
between age and delay (17, 32), while seven reported that younger age was 
predictive of longer waiting times (12, 22, 28, 41 , 46, 54, 5). Consistent with 
most of the literature, both univariate and multivariate analysis indicated that 
patients younger than 70 years old were more likely to experience longer waiting 
times than older patients. Sainsbury et al suggested that the association is due to 
physicians not expecting younger patients to have breast cancer because their risk 
is inherently lower (22). However, this explanation does not likely account for the 
finding in this study because women were already diagnosed and physicians 
would likely expect some women under 70 years of age to have cancer. Another 
possibility presented was that age is associated with delay because older women 
generally have more advanced disease. Again, this idea is not supported by this 
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study because the multiple regression indicated that age contributed 
independently to the prediction of waiting time. It is more likely that the 
difference can be attributed to the finding that older patients were more likely to 
be treated on the same day as their diagnosis, which would reduce the overall 
group mean. Age may contribute to the surgeon's choice to proceed to a 
definitive procedure immediately rather than subject an older patient to risks 
associated with multiple surgeries. Furthermore, it is likely that there are 
cosmetic considerations in the treatment decision of younger women and not with 
older women, allowing surgeons the freedom to perform the surgical treatment the 
day of the diagnosis. It is also possible that patient delay confounds the noted 
variation. Younger women might take longer in deciding between treatment 
options, leading to a perceived increase in system delay. The doubling time of 
breast cancer is quite long and based on this Dr. Susan Love's Breast Book 
recommend that patients take their time deciding their treatment (64). In order to 
verify these ideas and determine other possible accounts for the relationship 
between age and stage, further research needs to be conducted. It would be 
beneficial to begin with qualitative discussions with surgeons and other providers 
to elucidate their opinions on possible causes. 
Stage was also significantly associated with waiting time. Univariate and 
multivariate analyses specified that women diagnosed with Stage 1 disease waited 
significantly longer for their treatment than women with either Stage 2, 3 or 4 
disease. This finding was unexpected because Stage 1 and 2 are considered early 
stages of breast cancer, while Stage 3 and 4 are regarded as advanced disease. 
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Although studies have not specifically addressed the impact of stage, several did 
find the absence of a lump increased system delay (37, 41 , 46, 54). Because 
Stage 1 is defined by a tumor smaller than two centimeters (along with other 
factors) it is possible that some of these lumps would not be palpable allowing for 
comparison to results reported by other studies. For example, Caplan et al 
suggested that because lumps are the classical symptom of breast cancer, 
physicians expedited the care pathway when women presented this symptom. It 
is unlikely that this explains the association in this study because women were 
already diagnosed. One plausible interpretation is that the treatment decision for 
women with stage 1 is more difficult, leading to an increase in waiting while the 
patient and the physician agreed upon the surgical intervention. This does not 
explain why the univariate analysis indicated that stage 2 patients do not 
experience significantly more delay because their treatment options are similar to 
those for stage 1 patients. It is possible that stage was not accurately recorded in 
the data base, resulting in misclassification. Before further interpretation of the 
relationship between waiting time and stage, it is recommended that the reliability 
of the stage variables within the Alberta Cancer Registry be assessed by auditing 
patient charts. 
Multivariate analysis indicated that the absence of a recorded stage was 
predictive of delay, while univariate analysis did not portray a significant 
relationship. The contradictory findings could be the result of increased difficulty 
in proving significance with the nonparametric test used in the univariate analysis. 
No other studies reported interpretations of missing data. It is difficult to 
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speculate why women with no recorded stage on average waited longer for 
treatment because it is unknown why the stages were missing in the registry. 
Stage could be missing either because it is unknown or because it was not 
recorded in the chart from which the registry collects the data. A chart audit of 
patients with no recorded stage would help provide explanations for this finding. 
The RHA that the women lived in at diagnosis was also significantly 
associated with waiting time. Other studies have reported significant regional 
differences in other jurisdictions (27, 28, 30, 54). Tests specified that it was 
RHAs 1, 2, 4, and 6 that had significantly lower waiting times. These RHAs are 
all situated in southern Alberta and have at least a secondary cancer treatment 
centre. The Northern and Southern disparity was confirmed by a separate 
univariate analysis. Although the number of cases in the South and North are 
similar (3143 patients versus 3093 patients, respectively), four of the six southern 
RHAs have at least a secondary treatment centre compared to only two of 11 
Northern RHAs (Figure 2). Furthermore, three of the four secondary treatment 
centres are in Southern Alberta. It is feasable that the difference in waiting times 
in Southern and Northern Alberta was accounted for by the disproportionate 
number of secondary cancer treatment centres and capacity to initially manage 
breast cancer patients. This suggests that the secondary treatment centres reduce 
the demand on tertiary centres (RHAs 4 and 10) to provide treatment to women 
from surrounding RHAs. This explains the significant difference in the waiting 
times of RHA 4 and 10. However, it is not possible from this study to conclude 
whether the South does have more capacity to treat as a result of more treatment 
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centres because access to surgery is not related to existence of secondary centres. 
The first definitive treatment for most breast cancer cases will be surgery, which 
can occur outside of the cancer treatment centres. Therefore, it may be due to 
ecological fallacy that it appears that secondary centres are associated with 
reduced waiting times. The efficiency of the care pathway services could account 
for the disparity between the South and North. A comparison of the capacity (ie. 
specialists, surgeons, hospital beds, and other treatment resources) and the 
structure of the care pathway in Southern and Northern Alberta would help 
confirm if one or both of these explain the variation. 
Further support for the suggestion that secondary cancer treatment centres 
result in reduced delay was provided by the univariate analysis that indicated 
patients from rurban RHAs experienced significantly less delay than patients from 
urban and rural RHAs. RHAs were considered rurban if they had a secondary 
treatment centre within their boundaries. No significant difference in the delay of 
women from urban and rural RHAs was discovered. This finding was also 
confirmed by the lack of significance of community size in univariate and 
multivariate analyses. Caplan et al found that rural women were treated faster 
than urban patients, however, it is difficult to compare these findings because of 
the different definitions of rural and urban (28). It was an encouraging finding 
because it suggests that there is equal access for rural patients to health services 
that are centralized in larger communities. 
The final significant predictor of delay was the year in which women were 
diagnosed. Alarmingly, the median and mean waiting time for treatment 
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increased by an average of two days each year from 1997-2000. This is 
consistent with the study by Mayo et al that reported continual increases in 
waiting times for breast cancer patients in Quebec from 1992-1998 (29). The 
authors suggested that the annual increases in incidence of breast cancer and the 
aging population had resulted in more women requiring treatment for breast 
cancer, but resources had not increased accordingly, thereby, leading to longer 
delays. The absolute number of cases in this study did not increase each year. 
Therefore, the increased demand for treatment does not explain the average 
annual increase of two days. It was hypothesized that a decrease in the number of 
patients being treated the same day as their diagnosis because of changes in 
practice could account for the increase. A separate analysis of only those patients 
that waited one or more days for treatment disproved this idea, as the number of 
patients not waiting and the mean still increased each year. It is possible that the 
increase is spurious. Because we are only examining one portion of system delay, 
it does not indicate if the entire system delay period (from first physician visit to 
treatment) is increasing each year. It would be valuable to study the entire system 
interval as well as subintervals to determine if there are other trends of increase. 
It is recommended that the Alberta Cancer Registry include other significant dates 
of the care pathway in the database to facilitate further examination. 
Although there were five significant predictors of delay, the amount of 
variance accounted for by these variables was only nine percent. The inclusion of 
other variables could have explained more of the variation in waiting times. 
There was some evidence in the literature review that presenting symptom, 
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socioeconomic status (SES) and ethnic origin/race could influence the system 
delay interval (Table 5). Because this study examined the period after diagnosis, 
it is unlikely that presenting symptom would have influenced the waiting time. 
Studies examining the impact of SES and race on delay have been conducted in 
the United States and should be examined within the context of the Canadian 
medical system given the diversity of the population. Again, it would be 
important for the Alberta Cancer Board to collect this information. 
Likely environmental factors not included in the study or presented in the 
literature that could impact the delay interval are the specific treatment centre, 
surgeon providing the treatment, whether or not the patient was referred to a 
specialist or another surgeon for a second opinion, type of treatment, and travel 
distance. Treatment centres may impact waiting times because of differences in 
practice structure or capacity, which includes resources like the number of beds, 
operating rooms and surgeons. The treating surgeon also likely influences the 
waiting time because of dissimilarities in practice and available surgical operating 
time. Being referred to a specialist for treatment discussions or for a second 
opinion is another step in the care pathway that likely increases delay. The type of 
surgery that a woman receives could impact delay because of where specific 
treatments are offered and availability of these centres. It is possible that travel 
distance impacts waiting times in Alberta because of the centrality of treatment 
centres and the large area of the province. Examining these factors could help 
explain more of the waiting time variation. 
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5.4 Limitations and Strengths of Study 
This study had a number of potential weaknesses. Other potential 
predictors could have been Included to explain the variation in waiting time. This 
was a result of limited variables available in the Alberta Cancer Registry data 
base. It would have been beneficial to examine other potential predictors of 
delay, including SES, surgeon, treatment centre, whether or not patients were 
referred to another specialist after diagnosis, treatment type, and travel distance to 
treatment centre. Also not collected in the Registry were other important dates 
such as such as when the patient first detected a symptom of breast cancer, the 
first assessment by a physician and the first surgical consultation. As discussed 
earlier, there are a number of steps in the care pathway which could result in 
system delays. This study was only able to examine one of these intervals. 
Furthermore, there was no way to determine if some of the delay was attributable 
to the patient. It is possible that the patient contributed to longer delays by not 
accepting the diagnosis or missing appointments for treatment decision and 
surgery. This study assumes that the waiting times are only impacted by the 
system and its limitations. RHA boundary designation in Alberta is arbitrary, 
leading to difficulty explaining noted differences on a geographic basis. Finally, 
the large number of missing stage variables and the lack of quality control in 
assigning stages in the registry raises reliability questions regarding the 
interpretation of the results of stage. If an aggregate stage of TNM (tumor node 
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metastasis) components is not found in the chart, TNM components are identified 
and used to make the best estimate of stage by individual coders, not a 
pathologist. It is possible that some women are assigned an incorrect stage 
resulting in a misclassification bias. 
This study also had various strengths. The source of the data, the Alberta 
Cancer Registry, has been tested and awarded the highest quality level by an 
independent evaluator (59). The data obtained allowed the examination of four 
consecutive years. Moreover, it was a population based study that captured 95% 
of breast cancer patients in Alberta each year. This made the study very powerful 
and afforded more generalizable results than other studies that have used samples 
from specific treatment centres and smaller time frames. It can also provide other 
provinces in Canada information on waiting time expectations and factors that 
contribute to longer delays. 
5.5 Conclusions and Recommendations 
The findings from this study have significant implications for health care 
delivery. Although there continues to be no data indicating the optimal time 
frame within which a woman should receive treatment, an expert group has 
recommended that no more than two weeks transpire between diagnosis and 
treatment. It is important to meet this target based on evidence that long delays 
can lead to advanced stage and reduced survival. It is true that this relationship is 
still under debate because of contradictory findings, however, it is understandable 
that women waiting for treatment of breast cancer are facing a tremendous 
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amount of anxiety. Thus, it is recommended that efforts have to be made to 
reduce the waiting times experienced by patients in Alberta because the data from 
this study indicate that there is a trend of increased delay rather than a decrease. 
Questions of equal access to health services arise when centralization of 
health care services occurs, as it has in Alberta. The regional variation in waiting 
times between diagnosis and treatment established in this study suggests that 
patients from certain regions might have greater access to breast cancer services. 
Since this study began, the number of RHAs in Alberta has decreased from 17 to 
nine. Regardless of boundary designation, there is a significant difference in the 
waiting times of patients from Southern Alberta compared to those from Northern 
Alberta. These results should be disseminated to the RHAs and the Alberta 
Cancer Board for review. It is imperative that further examination of factors, 
including capacity, which could explain the significantly longer waiting times in 
the North, be conducted. Immediate implementation of solutions is important to 
ensure that some women are not inherently at a disadvantage because of where 
they live. 
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